

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Faculty Papers and Publications in Animal
Science

Animal Science Department

2019

Postnatal β 2 adrenergic treatment improves insulin sensitivity in lambs with IUGR but not persistent defects in pancreatic islets or skeletal muscle

Dustin T. Yates

Leticia E. Camacho

Amy C. Kelly

Leah V. Steyn

Melissa A. Davis

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.unl.edu/animalscifacpub>






Part of the [Genetics and Genomics Commons](#), and the [Meat Science Commons](#)

This Article is brought to you for free and open access by the Animal Science Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Papers and Publications in Animal Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Dustin T. Yates, Leticia E. Camacho, Amy C. Kelly, Leah V. Steyn, Melissa A. Davis, Andrew T. Antolic, Miranda J. Anderson, Ravi Goyal, Ronald E. Allen, Klearchos K. Papas, William W. Hay Jr, and Sean W. Limesand

Postnatal β_2 adrenergic treatment improves insulin sensitivity in lambs with IUGR but not persistent defects in pancreatic islets or skeletal muscle

Dustin T. Yates, Leticia E. Camacho, Amy C. Kelly , Leah V. Steyn, Melissa A. Davis, Andrew T. Antolic, Miranda J. Anderson, Ravi Goyal, Ronald E. Allen, Klearchos K. Papas, William W. Hay Jr  and Sean W. Limesand 

School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ, USA

Edited by: Laura Bennet & Janna Morrison

Key points

- Previous studies in fetuses with intrauterine growth restriction (IUGR) have shown that adrenergic dysregulation was associated with low insulin concentrations and greater insulin sensitivity.
- Although whole-body glucose clearance is normal, 1-month-old lambs with IUGR at birth have higher rates of hindlimb glucose uptake, which may compensate for myocyte deficiencies in glucose oxidation.
- Impaired glucose-stimulated insulin secretion in IUGR lambs is due to lower intra-islet insulin availability and not from glucose sensing.
- We investigated adrenergic receptor (ADR) β_2 desensitization by administering oral ADR β_2 modifiers for the first month after birth to activate ADR β_2 and antagonize ADR $\beta_1/3$. In IUGR lambs ADR β_2 activation increased whole-body glucose utilization rates and insulin sensitivity but had no effect on isolated islet or myocyte deficiencies.
- IUGR establishes risk for developing diabetes. In IUGR lambs we identified disparities in key aspects of glucose-stimulated insulin secretion and insulin-stimulated glucose oxidation, providing new insights into potential mechanisms for this risk.

Abstract Placental insufficiency causes intrauterine growth restriction (IUGR) and disturbances in glucose homeostasis with associated β adrenergic receptor (ADR β) desensitization. Our objectives were to measure insulin-sensitive glucose metabolism in neonatal lambs with IUGR and to determine whether daily treatment with ADR β_2 agonist and ADR $\beta_1/3$ antagonists for

Dustin Yates is an Assistant Professor of Stress Physiology in the Department of Animal Science, University of Nebraska-Lincoln. He earned his BS from Texas A&M University, MS with Mike Salisbury at Angelo State University and PhD with Tim Ross at New Mexico State University. He completed a postdoctoral fellowship in developmental biology with Sean Limesand at the University of Arizona. Dustin's research focuses on mechanisms linking prenatal stress with poor muscle growth and metabolic dysfunction. **Leticia Camacho** earned her MS in Animal Science with emphasis in physiology of reproduction from New Mexico State University under Dr Dennis Hallford. Leticia received her PhD in Reproductive Physiology from North Dakota State University with Dr Kimberly Vonnahme. She recently completed a NIFA USDA Postdoctoral Fellowship in perinatal biology and fetal programming with Dr Sean Limesand at the University of Arizona during which she investigated the adaptations in skeletal muscle growth and insulin-stimulated glucose metabolism in IUGR lambs.



D. T. Yates and L. E. Camacho contributed equally to this work.

1 month normalizes their glucose metabolism. Growth, glucose-stimulated insulin secretion (GSIS) and glucose utilization rates (GURs) were measured in control lambs, IUGR lambs and IUGR lambs treated with adrenergic receptor modifiers: clenbuterol atenolol and SR59230A (IUGR-AR). In IUGR lambs, islet insulin content and GSIS were less than in controls; however, insulin sensitivity and whole-body GUR were not different from controls. Of importance, ADR β 2 stimulation with β 1/ β 3 inhibition increases both insulin sensitivity and whole-body glucose utilization in IUGR lambs. In IUGR and IUGR-AR lambs, hindlimb GURs were greater but fractional glucose oxidation rates and *ex vivo* skeletal muscle glucose oxidation rates were lower than controls. Glucose transporter 4 (GLUT4) was lower in IUGR and IUGR-AR skeletal muscle than in controls but GLUT1 was greater in IUGR-AR. ADR β 2, insulin receptor, glycogen content and citrate synthase activity were similar among groups. In IUGR and IUGR-AR lambs heart rates were greater, which was independent of cardiac ADR β 1 activation. We conclude that targeted ADR β 2 stimulation improved whole-body insulin sensitivity but minimally affected defects in GSIS and skeletal muscle glucose oxidation. We show that risk factors for developing diabetes are independent of postnatal catch-up growth in IUGR lambs as early as 1 month of age and are inherent to the islets and myocytes.

(Resubmitted 29 July 2019; accepted after revision 28 October 2019; first published online 30 October 2019)

Corresponding author S. W. Limesand: School of Animal and Comparative Biomedical Sciences, The University of Arizona, 1650 E Limberlost Dr., Tucson, AZ 85719, USA. Email: limesand@email.arizona.edu

Introduction

Intrauterine growth restriction (IUGR) and early catch-up growth predict later development of chronic non-communicable metabolic disorders such as Type 2 diabetes and cardiovascular disease (Barker, 1990, 1993, 2002; Barker *et al.* 1993a, 2005, 2007; Soto *et al.* 2003; McMillen & Robinson, 2005; Whincup *et al.* 2008). Deficiencies in insulin secretion and insulin sensitivity manifest early in children that were born small-for-gestational-age (SGA) and eventually progress into more pronounced metabolic pathologies that characterize the metabolic syndrome (Barker *et al.* 1993b, 2002; Hofman *et al.* 1997; Li *et al.* 2001; Bazaes *et al.* 2004; McMillen *et al.* 2006, 2008; Eriksson, 2019). Recapitulating the causal link between fetal growth restriction and lifelong metabolic disorders in numerous experimental models across a variety of species has implicated adaptive developmental programming in response to placental insufficiency as the underlying mechanism (Simmons *et al.* 2001; Ford *et al.* 2007; Owens *et al.* 2007b; Jimenez-Chillaron *et al.* 2009; Gatford *et al.* 2010; Wallace *et al.* 2018; Chatmethakul & Roghair, 2019).

Fetuses with placental insufficiency experience progressive nutrient and oxygen deprivation and respond with greater noradrenaline (norepinephrine) and adrenaline (epinephrine) secretion (Greenough *et al.* 1990; Simonetta *et al.* 1997; Danielson *et al.* 2005; Limesand & Rozance, 2017). We found that when placental insufficiency was produced by maternal hyperthermia in sheep, the resulting fetal hypercatecholaminaemia inhibited insulin secretion and independently slowed growth (Leos *et al.* 2010; Limesand *et al.* 2013; Macko *et al.*

2013, 2016; Davis *et al.* 2015). Throughout life, individuals born SGA due to IUGR have less lean mass and reduced muscle strength, which is worsened by slower muscle accretion during infancy (Greenwood *et al.* 1998; Hediger *et al.* 1998; Gale *et al.* 2001; Sayer *et al.* 2004; Kensara *et al.* 2005; Inskip *et al.* 2007; Yliharsila *et al.* 2007). Despite less muscle mass, insulin sensitivity for glucose utilization is greater in IUGR fetal sheep, as their whole-body net glucose utilization rates are normal but plasma insulin and glucose concentrations are lower (Limesand *et al.* 2007; Thorn *et al.* 2013). However, the fraction of glucose utilized for oxidative metabolism is lower, which complements previous findings that chronic adrenergic receptor β (ADR β) stimulation increases non-oxidative glucose disposal (Scheidegger *et al.* 1984; Budohoski *et al.* 1987; Jensen *et al.* 2005; Limesand *et al.* 2007; Brown *et al.* 2015). We found that greater insulin sensitivity for glucose utilization persists in IUGR lambs at 2 weeks of age, but their higher plasma lactate concentrations may indicate that rates of glucose oxidation do not recover, resulting in lactate production; these results are similar to observations in children born SGA from IUGR (Jornayvaz *et al.* 2004; Camacho *et al.* 2017). Furthermore, glucose-stimulated insulin secretion (GSIS) was substantially greater in these IUGR lambs, which we associated with compensatory adaptations to high catecholamines *in utero* (Leos *et al.* 2010; Chen *et al.* 2014, 2017; Camacho *et al.* 2017; Kelly *et al.* 2018). These findings indicate a role for changes in ADR β signalling that creates a post-natal enhancement of GSIS and insulin-stimulated glucose utilization (Limesand & Rozance, 2017; Yates *et al.* 2018).

The three ADR β isoforms are expressed in a tissue-specific manner, and as G-protein coupled

receptors, their persistent activation lowers their own responsiveness (Collins *et al.* 1991; Wettschureck & Offermanns, 2005). In near-term IUGR fetuses and in 3-week-old IUGR lambs, we have shown that expression of ADR β 2 mRNA is downregulated in adipose tissue and skeletal muscle (Chen *et al.* 2010; Yates *et al.* 2012a). This ADR β 2 deficiency could explain restricted growth and muscle accretion in IUGR offspring because stimulation with ADR β 2 agonists repartitions nutrients in growing animals to support anabolic protein accretion and energy-producing oxidative pathways (Byrem *et al.* 1998; Consolo *et al.* 2015; Cadaret *et al.* 2017). Furthermore, deficiencies in glucose oxidation in IUGR fetal sheep and in adult humans born SGA from IUGR coincide with impaired proximal insulin signalling that may reflect the loss of counter-regulatory effects of adrenergic signalling (Hadcock *et al.* 1992; Morisco *et al.* 2005; Ozanne *et al.* 2005; Thorn *et al.* 2009). An interaction in signal transduction pathways has been demonstrated for ADR β 2 and insulin receptors, and lower ADR β 2 concentrations relative to ADR β 1 would favour inhibition of proximal insulin signalling (Baltensperger *et al.* 1996; Wang *et al.* 2000; Castle *et al.* 2001; Brennesvik *et al.* 2005; Gavi *et al.* 2007). Because this ADR β profile is still observed in young lambs with IUGR at birth, we hypothesize that the ADR β 2 effects to inhibit insulin receptors and insulin signalling continue postnatally even though insulin secretion is no longer suppressed (Muhlhauser *et al.* 2009; Chen *et al.* 2010; Camacho *et al.* 2017).

Although multiple factors may contribute to glucose intolerance, we postulate that selective desensitization of ADR β 2 after persistent exposure to hypercatecholaminaemia in late gestation represents an adaptive mechanism responsible for impaired skeletal muscle growth and insulin-sensitive glucose metabolism. Furthermore, previous studies of the fetal cardiovascular system indicate that sustained high concentrations of catecholamines lower ADR β responsiveness in the heart (Jones & Ritchie, 1978; Bassett *et al.* 1990; Bocking *et al.* 1995; Gardner *et al.* 2002). Therefore, we investigated whether selective ADR β 1 and ADR β 3 antagonists combined with an ADR β 2 agonist will normalize the predicted adrenergic dysregulation and improve early outcomes in growth, insulin secretion and action, and cardiovascular parameters in young lambs that were IUGR at birth.

Our objectives for this study were to determine deficiencies in insulin-stimulated glucose metabolism in 1-month-old lambs with IUGR at birth. We tested the hypothesis that these lambs have impaired GSIS and greater hindlimb glucose utilization rates. Furthermore, we postulate that these limitations result from intrinsic impairments for GSIS responsiveness of islets and for skeletal muscle insulin-stimulated glucose metabolism. Finally, we sought to determine

whether ADR β 2 activation via daily administration of pharmaceutical ADR β modifiers would increase insulin sensitivity for glucose metabolism and growth in IUGR lambs.

Methods

Ethical approval

Study protocols were approved by the Institutional Animal Care and Use Committee at The University of Arizona (Protocol no. 08-132) and follow the guidelines from the American Association for the Accreditation of Laboratory Animal Care International. All work was conducted at the university's Agricultural Research Centre. Pregnant Columbia–Rambouillet crossbred ewes were purchased from Nebeker Ranch (Lancaster, CA, USA), and those carrying singleton pregnancies were identified by ultrasonography prior to being assigned to an experimental group. The ewes were 2–4 years of age with unknown parity. Animals were managed as previously described (Chen *et al.* 2010), and these pregnant ewes (45 ± 2 kg) were assigned via simple randomization to the thermoneutral control group ($n = 16$) or the placental insufficiency-induced IUGR group ($n = 30$). Lambs born from the placental insufficiency-induced IUGR group (IUGR lambs) were produced using the maternal hyperthermia model (Chen *et al.* 2010; Camacho *et al.* 2017). Briefly, pregnant ewes were exposed to elevated ambient temperatures (40°C for 12 h; 35°C for 12 h; dew point 22°C) from 38 ± 1 to 87 ± 1 days of gestation. Control lambs were from ewes that were maintained at $22 \pm 1^\circ\text{C}$ and pair fed to the average *ad libitum* feed intake of the hyperthermic ewe group. All sheep were given *ad libitum* access to water and salt. One control and nine IUGR fetuses were lost prior to birth for undiagnosed reasons, leaving 15 controls and 22 IUGR lambs to be studied. Ewes delivered naturally and lambs were removed from the ewe to eliminate confounding maternal variability. Lambs were ear tagged and housed in adjacent individual pens in a separate location from their mothers. All lambs were fed colostrum four to six times over the first 36 h after birth before being reared solely on *ad libitum* milk replacer (Milk Specialties Co., Dundee, IL, USA). Body weight, crown–rump length (poll to tail head), hindlimb length (hip to hoof) and head circumference were measured at birth. The first seven IUGR lambs and six control lambs born were pre-selected for postnatal studies without being subjected to the postnatal intervention. The remaining IUGR lambs were randomly assigned to also receive either no postnatal intervention (IUGR; $n = 14$) or to receive daily oral ADR β modifiers (IUGR-AR, $n = 8$). This daily treatment consisted of $20 \mu\text{g kg}^{-1} \text{day}^{-1}$ clenbuterol (ADR β 2 agonist), $400 \mu\text{g kg}^{-1} \text{day}^{-1}$ atenolol (ADR β 1 antagonist) and $2 \mu\text{g kg}^{-1} \text{day}^{-1}$ SR59230A

(ADRB3 antagonist), given orally in 50 ml of milk replacer (Coleman *et al.* 1988; MacRae *et al.* 1988; Manara *et al.* 1996; Torneke *et al.* 1998; Chiou *et al.* 2000; Despres *et al.* 2002; Kanzler *et al.* 2011; Miniaci *et al.* 2013). The doses of clenbuterol, atenolol and SR59230A were chosen to provide the lowest effective dose in order to minimize potential off-target effects. Because of the prospective nature of the study and application of hyperthermia before the ability to determine fetal sex, the study did not take into account the sex distribution.

Physiological studies to measure insulin secretion and insulin sensitivity were performed on each lamb in no particular order and separated by at least 1 day. Growth rates were determined from body weights measured daily from birth (day 0) to day 29 of age. Absolute growth rates were linear over this period, and the R^2 (coefficient of determination) values of all slopes were ≥ 0.96 and not different among experimental groups. Growth rates as a percentage of birth weights were calculated by subtracting birth weight from daily body weight and then dividing by birth weight. Dry matter intake per gram of weight gained was used to determine daily feed-to-gain efficiency for each lamb (i.e. grams of milk consumed on a dry matter basis per gram of weight gained).

Surgical preparation

At 24 ± 1 days of age, lambs (15 control, 14 IUGR and 8 IUGR-AR) were fasted for 3–4 h. A jugular vein was used to administer diazepam (0.2 mg kg^{-1}) and ketamine (20 mg kg^{-1}) for induction, and the lambs were intubated and maintained by inhalation of 1.5–4% isoflurane in oxygen for the duration of the surgical procedure. The depth of anaesthesia was determined and maintained by response to touch, corneal reflex and assessment of muscle tone, as well as continuous pulse oximetry and heart rate monitoring. At induction, lambs received an intramuscular injection of penicillin G procaine injectable suspension ($1350 \text{ units (U) kg}^{-1}$; Agri-Cillin, Huvepharma, Inc., Peachtree City, GA, USA). In the non-study hindlimb, indwelling catheters (Tygon ND-100-80 Flexible Plastic Tubing; outer diameter 1.4 mm and inner diameter 0.9 mm) were surgically placed in the descending (abdominal) aorta and inferior vena cava via the femoral artery and vein for blood sampling and intravenous infusions. In the distal femoral vein of the contralateral hindlimb, a catheter was placed with the tip advanced to the external iliac vein and the deep circumflex iliac artery and vein were ligated and severed to isolate blood flow to the external iliac artery and vein. This hindlimb was designated the study limb. A Precision S-series Flow Probe (3 or 4 mm; Transonic Systems, Inc., Ithaca, NY, USA) was positioned around the external iliac artery of the study limb. Prior to placement, catheters

were filled with heparinized saline (30 U ml^{-1} , 0.9% w/v NaCl, Nova-Tech, Inc., Grand Island, NE, USA). After placement, the flow probe cable and the catheters were tunnelled subcutaneously to the flank, exteriorized through a skin incision, and kept in a plastic mesh pouch sutured to the skin. Lambs were given post-operative analgesics (0.01 g kg^{-1} body weight phenylbutazone) for 3 days and allowed to recover before performing studies. Catheters were flushed daily with heparinized saline.

Insulin secretion responsiveness to glucose and arginine

Glucose-stimulated insulin secretion (GSIS) was evaluated with a square-wave hyperglycaemic clamp at 28 ± 1 days of age as described previously (Camacho *et al.* 2017). Briefly, lambs were fasted for 3 h and then placed into the Panepinto sling. After approximately 20 min of acclimation, basal (fasted) blood samples were collected at -30 , -11 and -2 min for plasma glucose, insulin, cortisol, adrenaline and noradrenaline measurements. The hyperglycaemic clamp was initiated with an intravenous dextrose bolus ($250 \pm 20 \text{ mg kg}^{-1}$) followed by a constant infusion of 33% (w/v) dextrose solution that was adjusted to maintain arterial plasma glucose concentrations at approximately twice the basal glucose concentration observed for each lamb. Sample times are presented relative to administration of the dextrose bolus (time = 0). After the onset of the infusion, arterial blood samples were collected every 5 min for a minimum of 20 min to ensure that steady-state plasma glucose concentrations were achieved. Afterward, three blood samples were collected at approximately 30, 45 and 60 min. Steady-state hyperglycaemic conditions were considered to be confirmed when glucose concentrations varied less than $\pm 9\%$ from the overall mean. Acute, first-phase insulin concentrations were calculated for the first 20 min of hyperglycaemia and second-phase insulin concentrations were calculated during the hyperglycaemic clamp (30–60 min). Glucose-potentiated arginine-stimulated insulin concentration was determined with a follow-on arginine bolus (0.5 mmol kg^{-1}) to the GSIS study. One minute after the final GSIS sample was collected, the dose of arginine was administered over a 4 min period. Blood samples for plasma insulin concentrations were collected at 5 and 15 min after administering arginine.

Insulin sensitivity for glucose disposal rate

At 28 ± 1 days of age, glucose utilization rates were measured under basal (fasted) conditions and then again during a hyperinsulinaemic–euglycaemic

clamp as described previously (Camacho *et al.* 2017). Body weight-specific rates of glucose utilization were determined by the net disappearance rate of D-[^{14}C -U]glucose (PerkinElmer Life Sciences, Boston, MA, USA) during basal and hyperinsulinaemic steady-state periods. Lambs were fasted for 3 h and then placed into the Panepinto sling. A constant infusion (2 ml h^{-1}) of radiolabelled glucose ($37.2\text{ }\mu\text{Ci ml}^{-1}$) in saline was initiated following a 4 ml priming bolus. After 40 min, four arterial blood samples were collected at 8–10 min intervals and used to measure basal glucose utilization rates ($\mu\text{mol min}^{-1}\text{ kg}^{-1}$), plasma insulin, glucose and lactate concentrations, and arterial blood gases and oximetry. Hyperinsulinaemia was initiated with a priming dose of insulin (175 mU kg^{-1} ; HumulinR; Lilly; Indianapolis, IN, USA) followed by a constant infusion at 0.5, 2 or 4 $\text{mU min}^{-1}\text{ kg}^{-1}$. Each lamb was studied at a minimum of two hyperinsulinaemic periods. Euglycaemia was concurrently maintained with a 33% (w/v) dextrose infusion that was adjusted in response to arterial plasma glucose concentrations measured every 5–10 min until steady-state conditions were achieved, usually within an hour. Euglycaemia was considered to be at a steady state when arterial plasma glucose concentrations varied less than $\pm 9\%$ of the basal period mean. Arterial blood samples were collected at 8–10 min intervals.

For lambs in which hindlimb venous catheters remained patent on the day of the study ($n = 7$ controls, 5 IUGR, 5 IUGR-AR), hindlimb glucose uptake and oxidation rates were determined. Blood flow into the hindlimb through the exterior iliac artery was measured with the Transonic flow probe and recorded using LabChart software (ADInstruments, Colorado Springs, CO, USA). Venous blood samples from the study limb were collected simultaneously with arterial blood samples. Aliquots of arterial and venous whole blood samples were used to determine blood [^{14}C]glucose concentrations, blood $^{14}\text{CO}_2$ concentrations, blood oxygen content, and plasma glucose and lactate concentrations. Hindlimb glucose oxidation rates were measured at 0 $\text{mU min}^{-1}\text{ kg}^{-1}$ (basal) and 4 $\text{mU min}^{-1}\text{ kg}^{-1}$ hyperinsulinaemic–euglycaemic periods.

Heart rate and blood pressure

To confirm the functional presence of orally administered β_2 agonist clenbuterol along with β_1 antagonist atenolol and β_3 antagonist SR59230A we measured mean systemic arterial blood pressures and heart rates by attaching an externalized arterial catheter to a physiological pressure transducer that was connected to a PowerLab 8/35 with a bridge amplifier (ADInstruments Inc.). Pressures and heart rates were determined on three separate days and analysed with LabChart software. Pressure transducers

were calibrated with a mercury column manometer. Lambs were placed in the sling and physiological pressure transducers were set to the height of the heart. After an acclimation period of at least 10 min, data were recorded for a minimum of eight consecutive minutes under basal conditions. At 29 ± 1 days of age, lambs were challenged with the ADR β_1 agonist dobutamine HCl (12.5 mg ml^{-1} ; Hospira, Inc., Lake Forest, IL, USA) to evaluate cardiac responsiveness (Stephens *et al.* 2011). Data were recorded for 15 min during both basal and dobutamine-stimulated ($10\text{ }\mu\text{g min}^{-1}\text{ kg}^{-1}$) periods.

Biochemical analysis and calculations

Plasma glucose and lactate concentrations were measured with a YSI 2700 Select Biochemistry Analyzer (Yellow Springs Instruments, Yellow Springs, OH, USA). Blood gases and oximetry were measured in whole blood collected in heparin-lined syringes (Elkins-Sinn, Cherry Hill, NJ, USA) using an ABL720 (Radiometer, Copenhagen, Denmark). Values were temperature-corrected for the rectal temperature of the lamb measured at the start of the study. Whole blood [^{14}C]glucose was determined in supernatants after being deproteinized by mixing whole blood with 0.3 N zinc sulfate heptahydrate and 0.3 M barium hydroxide. The supernatant was separated into triplicate aliquots and dried. Radioactivity was measured with a LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter, Fullerton, CA, USA) in Hionic Fluor Liquid Scintillation Cocktail (PerkinElmer Inc., Waltham, MA, USA). Plasma hormone concentrations were determined by enzyme-linked immunosorbent assay (ELISA) for insulin (Ovine Insulin ELISA; ALPCO Diagnostics, Windham, NH, USA; sensitivity 0.14 ng ml^{-1} intra- and interassay coefficients of variation, 3% and 6%, respectively), cortisol (Oxford Biomedical Research, Oxford, MI, USA; sensitivity 10 pg ml^{-1} ; intra- and inter-assay coefficients of variation, 9% and 12%, respectively), noradrenaline (Labor Diagnostika Nord, Nordhorn, Germany; sensitivity, 25 pg ml^{-1} ; intra- and inter-assay coefficients of variation, 6% and 14%, respectively) and adrenaline (Labor Diagnostika Nord; sensitivity, 8.3 pg ml^{-1} ; intra- and interassay coefficients of variation, 11% and 17%, respectively). The $^{14}\text{CO}_2$ was released from triplicate aliquots of whole blood with 2 N HCl, captured in Solvable (PerkinElmer Inc.), and measured in Ultima Gold scintillation cocktail (PerkinElmer Inc.).

Whole-body net glucose utilization rates ($\mu\text{mol min}^{-1}$) were calculated as the ratio of [^{14}C]glucose infusion rate (d.p.m. min^{-1}) to arterial whole blood [^{14}C]glucose specific activity ($\text{d.p.m. }\mu\text{mol}^{-1}$ glucose). Endogenous (hepatic) glucose production rates were calculated as the difference between the whole-body net glucose utilization

rate and exogenous dextrose (D-glucose) infusion rate ($\mu\text{mol min}^{-1}$). All rates were normalized to body weight (kg). Insulin sensitivity for glucose utilization rate ($\mu\text{mol min}^{-1} \text{ kg}^{-1} \mu\text{g}^{-1} \text{ l}^{-1}$) was calculated as the body weight-specific net glucose utilization rate ($\mu\text{mol min}^{-1} \text{ kg}^{-1}$) divided by the arterial plasma insulin concentration ($\mu\text{g l}^{-1}$).

Hindlimb metabolic flux calculation

Mean hindlimb glucose, lactate, [^{14}C]glucose and $^{14}\text{CO}_2$ fluxes were calculated from the simultaneously collected femoral arterial and venous blood sample pairs. Weight-specific net uptake rates of oxygen, [^{14}C]glucose and glucose as well as outputs of lactate were calculated by the Fick principle as the product of artery blood flow and arteriovenous difference (Rozance *et al.* 2018). Arterial blood [^{14}C]glucose concentrations (d.p.m. ml^{-1}) were divided by arterial blood glucose concentrations ($\mu\text{mol ml}^{-1}$) to determine specific activity (d.p.m. μmol^{-1}). All net hindlimb uptakes and output rates were normalized to hindlimb weight (kg) measured at necropsy. Glucose and lactate oxygen quotients were calculated as six or three times, respectively, the ratio of the arteriovenous difference of the respective carbohydrate to the arteriovenous difference of oxygen. The fractional extraction (%) of glucose across the hindlimb was calculated as the arteriovenous difference in plasma glucose concentration divided by the arterial plasma glucose concentration.

Post-mortem

Lambs were killed at 31 ± 1 days with an intravenous overdose of sodium pentobarbital (86 mg kg^{-1}) and phenytoin sodium (11 mg kg^{-1} ; Euthasol; Virbac Animal Health). At necropsy, pancreatic ducts were perfused with a collagenase solution (0.5 mg ml^{-1} Collagenase V, Sigma-Aldrich, St Louis, MO, USA; 0.02% DNase I, Roche, Indianapolis, IN, USA; in Krebs–Ringer buffer (KRB), $118 \text{ mmol l}^{-1} \text{ NaCl}$, $4.8 \text{ mmol l}^{-1} \text{ KCl}$, $25 \text{ mmol l}^{-1} \text{ NaHCO}_3$, $1.2 \text{ mmol l}^{-1} \text{ MgSO}_4$, $1.2 \text{ mmol l}^{-1} \text{ KH}_2\text{PO}_4$, $2.5 \text{ mmol l}^{-1} \text{ CaCl}_2$) as described previously (Limesand *et al.* 2006). The pancreas was removed by blunt dissection, submerged in the collagenase solution, and incubated at 37°C for 20 min with gentle mixing every 3 min for islet isolation. Organs (brain, liver, heart, kidneys and lungs) and perirenal adipose tissue were dissected and weighed. Mid-sections of semitendinosus, semimembranosus and bicep femoris muscles were collected for cell isolation or were frozen. The study limb was disarticulated at the proximal end of the femur and weighed. Tissue samples were snap-frozen in liquid nitrogen and stored at -80°C for enzyme and immunoblot analysis.

Pancreatic islet isolation and functional assessments

Digested pancreas tissue was filtered through a $500 \mu\text{m}$ mesh filter and was washed three times by sedimentation in KRB containing 0.5% bovine serum albumin (BSA). Pancreas tissue that did not pass through the mesh filter was subjected to an additional 20 min digestion in collagenase solution and then filtered and washed. Islets were partially purified with a discontinuous gradient of polysucrose 400 (Corning cellgro, Corning, NY, USA) diluted with Hank's balanced salt solution (Gibco HBSS; Thermo Fisher Scientific, Waltham, MA, USA) to 25% , 23% , 20% and 11% dilutions. After being centrifuged at $1400 g$ for 20 min, islets were removed from the 20% layer and were washed three times in KRB–BSA. Islets were incubated overnight in RPMI 1640 (Sigma-Aldrich) supplemented with 5% fetal bovine serum and penicillin–streptomycin–neomycin ($0.1 \text{ mg ml}^{-1} - 0.1 \text{ mg ml}^{-1} - 0.2 \text{ mg ml}^{-1}$) at 37°C in $95\% \text{ O}_2 - 5\% \text{ CO}_2$.

Islets were incubated for 60 min in KRB–BSA prior to functional assessments. Islets (~ 200 per lamb) from each lamb were re-suspended in Media 199 (Corning Mediatech, Inc., Tewksbury, MA, USA) that had been pre-warmed to 37°C and were divided evenly between three chambers of a Fluorescence Lifetime Micro Oxygen Monitoring System (Instech Laboratories, Inc., Plymouth Meeting, PA, USA) (Papavas *et al.* 2007; Smith *et al.* 2017). Measurements of partial pressure of O_2 (P_{O_2}) in each chamber were recorded over time using fibre optic sensors and NeoFox viewer software (Instech Laboratories, Inc.). Oxygen consumption rates (OCRs; $\text{nmol O}_2 \text{ min}^{-1}$) were determined from the slope of P_{O_2} disappearance over time and normalized to the DNA content of islets in each chamber (OCR/DNA; $\text{nmol O}_2 \text{ min}^{-1} (\text{mg DNA})^{-1}$). Islet DNA was extracted with a 1 N ammonium hydroxide and 0.2% Triton X-100 solution and DNA content was determined in triplicate with Quant-iT PicoGreen dsDNA kit (Thermo Fisher Scientific) according to manufacturer instructions. Oxygen consumption rates were measured in control and IUGR islets only.

Insulin secretion from isolated islets was measured by perfusion (Biorep Technologies Perfusion System, Peri-4.2; Miami Lakes, FL, USA). GSIS was measured in triplicate with 75 islets per perfusion chamber at a flow rate of $100 \mu\text{l min}^{-1}$. KRB–BSA that was supplemented with glucose (0.5 or 11.1 mmol l^{-1}) or KCl (30 mmol l^{-1} with 1.1 mmol l^{-1} glucose), pre-warmed to 37°C , and oxygen-saturated ($95\% \text{ O}_2 - 5\% \text{ CO}_2$) was used in islet perfusions. Following a 40 min baseline period at 0.5 mM glucose, islets were stimulated for 40 min with 11.1 mmol l^{-1} glucose (GSIS) and subsequently with KCl–glucose (maximal response). Samples were collected and stored at -80°C , and insulin concentrations were subsequently measured with an ovine insulin ELISA. First

phase insulin secretion was determined over the first 11 min of high glucose and second phase insulin secretion was determined between 20 and 40 min by calculating the area under the curve for these time frames. Islet preparations that were unresponsive to KCl stimulation were excluded from the analysis. Islet insulin contents were determined in five replicates of 10 islets as described previously (Limesand *et al.* 2006).

Ex vivo skeletal muscle glucose oxidation rates

Longitudinal strips of semitendinosus muscle (6 technical replicates per condition for each lamb) were isolated and glucose oxidation rates were determined as described previously (Cadaret *et al.* 2017) with some modifications. Muscle strips (30–50 mg) were dissected, mounted in Plexiglas U-clamps, and placed in 6-well plates (Costar, Corning Inc., Kennebunk, ME, USA). Muscle strips were pre-incubated for 1 h at 37°C (95% O₂: 5% CO₂) in oxygen-saturated Krebs–Henseleit bicarbonate buffer (KHB, pH 7.4) supplemented with 0.1% BSA, 5 mmol l⁻¹ D-glucose and 32 mmol l⁻¹ D-mannitol (Sigma-Aldrich). Muscle strips were then incubated in KHB media containing no added hormones (basal), insulin (10 µU ml⁻¹ Humulin R), insulin + catecholamines (12.5 µmol l⁻¹ adrenaline, 12.5 µmol l⁻¹ noradrenaline), or insulin + cytochalasin B (20 mmol l⁻¹; Sigma-Aldrich) for 30 min. Finally, muscle strips were incubated for 1 h in the above treatment media supplemented with D-[¹⁴C-U]glucose (2 µCi ml⁻¹). Glass microfibre filters (Whatman GF/D; GE Healthcare Life Sciences, Little Chalfont, UK) were saturated with 1 M NaOH and suspended over each well of the plate, which was sealed with a plastic gasket. After 1 h, 1 N HCl was injected into each well. Plates were incubated for 2 h at room temperature, the filter papers were removed and radioactivity from captured ¹⁴CO₂ was measured via liquid scintillation in Biosafe II Scintillation cocktail (Research Products International Corp., Mount Prospect, IL, USA). Muscle strips were removed from clamps and weighed. Specific activity for glucose (d.p.m. pmol⁻¹) was determined and data are expressed as picomoles per milligram of tissue per hour.

Skeletal muscle glycogen content, citrate synthase activity and immunoblots

Glycogen contents and citrate synthase activities were determined in semitendinosus muscles collected at necropsy as described previously (Camacho *et al.* 2017). Glucose concentrations from the extracted glycogen were determined in triplicate, and results are expressed as milligrams of glucose per gram of tissue (wet weight). Citrate synthase activity was measured with the citrate synthase

assay kit (Sigma-Aldrich) from 20 µg of protein and are expressed as activity per microgram of protein.

Immunoblots were performed on protein lysates prepared from semitendinosus muscle (30–40 mg) with CellLytic MT Cell Lysis Reagent (Sigma-Aldrich) and protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg ml⁻¹ Aprotinin, 2.5 µg ml⁻¹ Leupeptin) as described previously (Camacho *et al.* 2017). Primary antibodies used were raised in rabbit against glucose transporter 1 (GLUT1, 1:250, Millipore Cat. no. 07-1401, lot no. 2630748, RRID:AB_1587074), glucose transporter 4 (GLUT4, 1 µg ml⁻¹, Sigma-Aldrich Cat. no. G4048, lot no. 016M4809V, RRID:AB_1840900), ADRβ2 (ADRB2; 1:250, Santa Cruz Biotechnology Cat. no. sc-569, lot no. G3115, RRID:AB_630926), insulin receptor β-subunit (INSR, 1:250, Santa Cruz Biotechnology Cat. no. sc-711, lot no. H0916, RRID:AB_631835) and Tubulin-β (TUBB; 1:1000, Thermo Fisher Scientific no. RB-9249-P0, lot no. 9249P1507B and 9249P1603L, RRID:AB_722289). Antibody complexes were detected with anti-rabbit IgG horseradish peroxidase conjugated secondary antibody (1:15,000; Bio-Rad Laboratories, Hercules, CA, USA) and chemiluminescence (West Pico Chemiluminescent Substrate; Thermo Fisher). Protein concentrations were quantified using photographed images and densitometry analyses (Scion Image Software, Frederick, MD, USA). Protein loading was normalized with Tubulin-β concentrations. To accommodate the number of samples, two immunoblots were run simultaneously that contained overlapping samples for internal controls. Data are presented as percentage of the control mean.

Statistical analysis

Lamb morphometric characteristics, citrate synthase activity, glycogen content, protein expression, arterial blood pressure, heart rate and dobutamine responses were analysed by ANOVA for group effects using the MIXED procedure of SAS 9.4 (SAS Institute, Cary, NC, USA). Differences were determined with a *post hoc* Fisher's least significant difference test. Growth rates and growth rates/birth weights were examined using repeated measures analysis of the MIXED procedure. Factors included in the repeated measure models were experimental group, time (day) and their interaction. Means were separated using the PDIF option of the LSMEANS statement of SAS. The GSIS and arginine-stimulated insulin secretion studies were analysed by ANOVA using the MIXED procedure. The model included experimental groups (control, IUGR and IUGR-AD), draw time, and their interaction. Appropriate (minimize information criterion) covariance structures were selected using the best fit statistics. *In vivo* rates

Table 1. Birth morphometry

Group (n)	Control (15)	IUGR (14)	IUGR-AR (8)
Sex (M:F)	9:6	3:11	2:6
Gestational age (day)	151 ± 1 ^a	149 ± 1 ^b	148 ± 1 ^b
Birth weight (kg)	4.3 ± 0.2 ^a	2.9 ± 0.3 ^b	2.5 ± 0.4 ^b
Crown-rump length (cm)	49.7 ± 1.0 ^a	43.3 ± 1.6 ^b	41.6 ± 1.9 ^b
Hindlimb length (cm)	40.9 ± 1.8	36.8 ± 2.2	38.6 ± 3.6
Head circumference (cm)	24.9 ± 0.7	22.4 ± 0.9	20.7 ± 0.8
Head circumference/weight	5.9 ± 0.2 ^a	8.5 ± 0.7 ^b	9.5 ± 1.1 ^b

Animal numbers (n) within groups are presented in parentheses. Data are expressed as the mean ± SEM. Differences ($P < 0.05$) between groups are identified with different superscript letters.

and fluxes were analysed by ANOVA using the MIXED procedure with lamb as the random effect. Main effects were experimental group (control, IUGR and IUGR-AR lambs), study period defined by the insulin infusion rate (basal and hyperinsulinaemia) and their interaction. *Ex vivo* muscle glucose oxidation rates were analysed by ANOVA with the MIXED procedure for effects of experimental group, media condition (basal, insulin, insulin + catecholamines, or insulin + cytochalasin B), and their interaction. The main effect of sex was not tested due to insufficient power in the IUGR and IUGR-AR groups. Means were separated using the Fisher's least significant difference test and were considered significant when $\alpha \leq 0.05$. In the absence of interactions ($P > 0.05$), significant main effects are reported; otherwise, interactive means are discussed. Lamb was considered the experimental unit for all outputs. Data are presented as the mean ± standard error of the mean.

Results

Morphometry at birth and postnatal growth


Morphometric measurements at birth, sex ratios and gestational lengths for lambs are presented in Table 1. At birth, IUGR and IUGR-AR lambs were lighter, had shorter crown-rump lengths, and had reduced head circumference-to-body weight ratios than controls.

Control lambs were heavier than IUGR and IUGR-AR lambs throughout the 30-day period (Fig. 1A). Absolute growth rates were greater ($P < 0.01$) in control lambs ($292 \pm 14 \text{ g day}^{-1}$) than in IUGR ($209 \pm 17 \text{ g day}^{-1}$) or IUGR-AR ($175 \pm 19 \text{ g day}^{-1}$) lambs, but IUGR and IUGR-AR growth rates were not different from each other. Growth as a percentage of birth weight was not

different among groups (Fig. 1B). Feed-to-weight gain efficiencies were not different among groups (0.77 ± 0.04 , 0.78 ± 0.04 and $0.81 \pm 0.05 \text{ g g}^{-1}$ for control, IUGR and IUGR-AR lambs, respectively). At 28 ± 1 days of age, IUGR ($8.4 \pm 0.6 \text{ kg}$) and IUGR-AR ($6.9 \pm 1.0 \text{ kg}$) lambs weighed less ($P < 0.05$) than control lambs ($12.5 \pm 0.5 \text{ kg}$).

Cardiovascular measurements

Cardiovascular measurements were conducted to confirm the functional presence of administered $\text{ADR}\beta$ pharmacological modulators. Mean arterial blood pressure was not different among experimental groups (Fig. 2A). Resting heart rate was higher in IUGR and IUGR-AR lambs compared to control lambs (Fig. 2B). Administration of the $\text{ADR}\beta 1$ agonist dobutamine increased heart rates in control lambs by $118 \pm 15 \text{ beats min}^{-1}$ from basal, which was of greater magnitude ($P < 0.05$) than the $73 \pm 15 \text{ beats min}^{-1}$ increase in IUGR lambs. There was no response to dobutamine in IUGR-AR lambs, which was expected due to the ongoing oral administration of the $\text{ADR}\beta 1$ inhibitor atenolol (Fig. 2C).

**Figure 1. Lamb growth**

A, average daily weights are presented for control ($n = 15$), IUGR ($n = 14$) and IUGR-AR ($n = 8$) lambs. B, daily weights as a percentage of birth weight are presented for lambs in each experimental group. Different letters on the right side of A indicate group differences.

Glucose- and arginine-stimulated insulin concentrations

Fasting plasma glucose concentrations were not different among groups, and glucose and insulin concentrations increased ($P < 0.05$) during the hyperglycaemia clamp (Fig. 3). Fasting plasma insulin concentrations were lower in IUGR lambs compared to control lambs, but there was no difference between IUGR and IUGR-AR groups. For first-phase GSIS, glucose concentrations were greater in IUGR-AR lambs compared to IUGR and control lambs, whereas, first-phase insulin concentrations were lower in IUGR and IUGR-AR lambs compared to control lambs. For second-phase GSIS, glucose concentrations remained greater in IUGR-AR lambs compared to IUGR and control

lambs, but not different between IUGR and control lambs. Second-phase insulin concentrations remained lower in IUGR lambs compared to control lambs, but insulin concentrations in IUGR-AR lambs were intermediate to control and IUGR lambs. Glucose-potentiated arginine-stimulated insulin concentrations were similar among experimental groups (mean values for controls $31.8 \pm 5.2 \mu\text{g l}^{-1}$, IUGR lambs $30.7 \pm 4.5 \mu\text{g l}^{-1}$, IUGR-AR lambs $27.4 \pm 5.3 \mu\text{g l}^{-1}$).

Plasma cortisol concentrations were greater in IUGR-AR lambs compared to IUGR and control lambs (Table 2). Plasma adrenaline and noradrenaline concentrations were not different among groups.

Whole-body insulin sensitivity for glucose utilization

The dose–response relationship between plasma insulin concentrations and whole-body net glucose utilization




Figure 2. Mean arterial blood pressure and heart rates

Mean arterial pressure (A) and heart rate (B) are presented for control ($n = 12$; 7 male (M)/5 female (F)), IUGR ($n = 14$; 3M/11F) and IUGR-AR ($n = 7$; 1M/6F) lambs. Dobutamine response (C) was calculated as the difference in heart rate between stimulated and unstimulated periods for control ($n = 4$; 3M/1F), IUGR ($n = 4$; 2M/2F) and IUGR-AR ($n = 7$; 1M/6F) lambs. Differences ($P < 0.05$) between experimental groups are indicated by different letters.




Figure 3. Glucose stimulated insulin concentrations


Square-wave hyperglycaemic clamps were performed in control ($n = 12$; 7M/5F), IUGR ($n = 13$; 3M/10F) and IUGR-AR ($n = 7$; 1M/6F) lambs at 28 days of age. Mean (\pm SEM) plasma glucose (A) and insulin (B) concentrations are presented for basal (fasting), first-phase (0–15 min) and second-phase (20–60 min) periods of the GSIS study. The different letters above the bars represent significant difference between means ($P < 0.05$).

Table 2. Plasma cortisol and catecholamine concentrations

Group (n)	Control (12)	IUGR (13)	IUGR-AR (7)
Cortisol ($\mu\text{g l}^{-1}$)	22.8 \pm 5.9 ^a	24.4 \pm 5.6 ^a	46.2 \pm 7.4 ^b
Adrenaline (ng l ⁻¹)	109 \pm 37	131 \pm 17	102 \pm 28
Noradrenaline (ng l ⁻¹)	573 \pm 80	1076 \pm 337	842 \pm 304

Animal numbers (n) within groups are presented in parentheses. Data are expressed as the mean \pm SEM. Differences ($P < 0.05$) between groups are identified with different superscript letters. Plasma samples were collected during the basal period of the GSIS study.

rates was best fitted ($R^2 = 0.64$) by the Michaelis–Menten equation shown in Fig. 4, which estimated insulin responsiveness (maximum glucose utilization rate) at $65 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$ and insulin sensitivity (insulin concentration needed for half-maximum glucose utilization rate) at $1.0 \pm 0.1 \mu\text{g l}^{-1}$. Lambs from control and IUGR groups had similar blood glucose concentrations under all conditions ($6.0 \pm 0.2 \text{ mmol l}^{-1}$). Plasma insulin concentrations and body weight-specific net glucose utilization rates used to generate the dose–response curves were not different between control ($V_{\text{max}} 68 \pm 3 \mu\text{mol min}^{-1} \text{kg}^{-1}$, $K_m 1.3 \pm 0.2 \mu\text{g l}^{-1}$) and IUGR lambs ($V_{\text{max}} 63 \pm 3$, $K_m 0.9 \pm 0.2$) at any

**Figure 4. Whole-body glucose utilization rate dose–response to insulin**

Body weight-specific net glucose utilization rates were determined in control ($n = 14$; 8M/6F) and IUGR ($n = 14$; 3M/11F) lambs at 28 days of age. No differences were found between IUGR and control groups, and all lambs were combined to evaluate the dose–response relationship. Glucose utilization rates were measured at basal and three hyperinsulinaemic–euglycaemic periods by infusing insulin at 0.5, 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$. Each lamb was evaluated at two or three steady-state periods. Insulin concentrations ($\mu\text{g l}^{-1}$) are plotted on the x-axis and net glucose utilization rates ($\mu\text{mol min}^{-1} \text{kg}^{-1}$) on the y-axis. A Michaelis–Menten equation ($R^2 = 0.64$) was used to predict maximum rate of glucose utilization ($65 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$) and half-maximum insulin concentration ($1.0 \pm 0.1 \mu\text{g l}^{-1}$) for glucose utilization rate in lambs.

infusion rate, and these two groups were combined to analyse this relationship. Plasma insulin concentrations also did not differ between basal and 0.5 $\text{mU min}^{-1} \text{kg}^{-1}$ infusion rates (1.5 ± 0.2 and $3.1 \pm 1.2 \mu\text{g l}^{-1}$, respectively) among groups. However, plasma insulin concentrations increased ($P < 0.01$) sequentially at 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$ infusion rates (8.4 ± 1.3 and $20.5 \pm 3.2 \mu\text{g l}^{-1}$, respectively). Whole-body glucose utilization rates increased ($P \leq 0.05$) sequentially from the basal period ($35 \pm 1 \mu\text{mol min}^{-1} \text{kg}^{-1}$) to each subsequent insulin infusion rate at 0.5 $\text{mU min}^{-1} \text{kg}^{-1}$ ($39 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$), 2 $\text{mU min}^{-1} \text{kg}^{-1}$ ($52 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$) and 4 $\text{mU min}^{-1} \text{kg}^{-1}$ ($65 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$).

Based on the dose–response curve, insulin infusion rates of 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$ were evaluated to determine insulin sensitivity for whole-body net glucose utilization rates. No interactions were found between groups or insulin infusion rate for glucose concentrations, insulin concentrations, glucose utilization rates, or endogenous glucose production rates, which indicates that all lambs had similar responses to the increased insulin infusion rates. Blood glucose concentrations were not different among all groups or between the different insulin infusion rates (Fig. 5A). Plasma insulin concentrations were not different among groups within any infusion period, but average insulin concentrations across all groups increased ($P < 0.01$) from basal ($1.5 \pm 0.2 \mu\text{g l}^{-1}$), as expected, when insulin was infused at 2 $\text{mU min}^{-1} \text{kg}^{-1}$ ($10.0 \pm 1.7 \mu\text{g l}^{-1}$) and 4 $\text{mU min}^{-1} \text{kg}^{-1}$ ($26.2 \pm 4.5 \mu\text{g l}^{-1}$; Fig. 5B). Regardless of the insulin infusion rate during the study, whole-body net glucose utilization rates were greater in IUGR-AR lambs ($62 \pm 4 \mu\text{mol min}^{-1} \text{kg}^{-1}$) than in IUGR ($50 \pm 3 \mu\text{mol min}^{-1} \text{kg}^{-1}$) and control lambs ($51 \pm 3 \mu\text{mol min}^{-1} \text{kg}^{-1}$; Fig. 5C). Endogenous glucose production rates decreased from basal periods ($39 \pm 2 \mu\text{mol min}^{-1} \text{kg}^{-1}$) when insulin was infused at 2 $\text{mU min}^{-1} \text{kg}^{-1}$ ($18 \pm 3 \mu\text{mol min}^{-1} \text{kg}^{-1}$) or 4 $\text{mU min}^{-1} \text{kg}^{-1}$ ($10 \pm 3 \mu\text{mol min}^{-1} \text{kg}^{-1}$), but were not different among groups for either insulin infusion rate (Fig. 5D). There was a group by insulin infusion rate interaction ($P < 0.05$) for insulin sensitivity (Fig. 5E); under basal conditions, insulin sensitivity was greater in IUGR-AR lambs than in control or IUGR lambs. During either hyperinsulinaemic period, insulin sensitivity was lower than at basal conditions but was not different among all groups.

Hindlimb metabolic fluxes

Arterial blood oxygen content, plasma glucose and lactate concentrations, and hindlimb oxygen uptake rates, lactate output rates and nutrient oxygen quotients measured during the hyperinsulinaemic–euglycaemic clamps are presented in Table 3. No interaction between experimental

groups and insulin infusion rates was observed for any of these variables. Plasma glucose concentrations, blood oxygen content and hindlimb net oxygen uptake rates were not different among groups or at the two insulin infusion rates. Plasma lactate concentrations were similar between

IUGR lambs ($0.73 \pm 0.08 \text{ mmol l}^{-1}$) and IUGR-AR lambs ($0.92 \pm 0.08 \text{ mmol l}^{-1}$) but were greater ($P < 0.05$) than in control lambs ($0.50 \pm 0.07 \text{ mmol l}^{-1}$). Hindlimb lactate output rates and lactate oxygen quotients were not different among groups or at the two insulin infusion rates.




Figure 5. Whole-body glucose utilization rates

Hyperinsulinaemic–euglycaemic clamps were performed in control ($n = 14$; 8M/6F), IUGR ($n = 14$; 3M/11F) and IUGR-AR ($n = 7$; 1M/6F) lambs at 28 days of age. Whole-body net glucose utilization rates were measured at basal and two hyperglycaemic periods created with sequential increases in the insulin infusion rate (0, 2 and $4 \text{ mU min}^{-1} \text{ kg}^{-1}$), which are indicated on the x-axis. Experimental group means \pm SEM are presented for blood glucose concentrations (A), plasma insulin concentrations (B), body weight-specific glucose utilization rates (C), endogenous glucose production rates (D) and insulin sensitivity (E). Main effects in the two-way ANOVA included experimental group, study period for the insulin infusion rate, and their interaction (group by period). P values are presented for these effects if they were significant ($P \leq 0.05$). For an interaction, differences ($P \leq 0.05$) are identified by different letters.

Table 3. Hindlimb metabolic flux measurements for arterial oxygen, lactate and glucose concentrations, oxygen and lactate uptakes, and metabolic quotients

Experimental group	Insulin infusion rate									P values		
	0 mU min ⁻¹ kg ⁻¹			2 mU min ⁻¹ kg ⁻¹			4 mU min ⁻¹ kg ⁻¹					
	Control	IUGR	IUGR-AR	Control	IUGR	IUGR-AR	Control	IUGR	IUGR-AR	G	P	I
Hindlimb blood flow (ml min ⁻¹)	55 ± 4	46 ± 5	47 ± 5	53 ± 6	38 ± 2	44 ± 7	52 ± 6	44 ± 5	46 ± 5	0.31	0.10	0.26
Hindlimb blood flow (ml min ⁻¹ kg ⁻¹)	45 ± 4	64 ± 7	64 ± 6	43 ± 5	54 ± 9	62 ± 7	42 ± 5	62 ± 10	61 ± 7	0.08	0.11	0.28
Blood oxygen (mmol l ⁻¹)	7.0 ± 0.2	6.8 ± 0.3	6.2 ± 0.5	6.9 ± 0.3	6.8 ± 0.4	6.6 ± 0.3	7.0 ± 0.3	6.8 ± 0.3	6.2 ± 0.5	0.25	0.95	0.86
Oxygen uptake (μmol min ⁻¹ kg ⁻¹)	103 ± 14	131 ± 15	124 ± 5	109 ± 12	138 ± 24	149 ± 15	106 ± 12	153 ± 36	126 ± 13	0.14	0.28	0.42
Plasma lactate (mmol l ⁻¹)	0.52 ± 0.04	0.60 ± 0.08	1.01 ± 0.16	0.45 ± 0.03	0.71 ± 0.10	0.74 ± 0.09	0.54 ± 0.04	0.87 ± 0.19	0.98 ± 0.20	<0.01	0.19	0.45
Lactate uptake (μmol min ⁻¹ kg ⁻¹)	-6.9 ± 0.9	-8.5 ± 1.4	-11.3 ± 2.1	-6.8 ± 1.0	-12.7 ± 4.2	-11.6 ± 2.3	-7.3 ± 1.5	-11.7 ± 2.4	-12.0 ± 1.1	0.10	0.14	0.44
Lactate O ₂ quotient	-0.22 ± 0.04	-0.21 ± 0.04	-0.27 ± 0.04	-0.20 ± 0.04	-0.28 ± 0.09	-0.23 ± 0.04	-0.22 ± 0.04	-0.22 ± 0.03	-0.29 ± 0.01	0.63	0.92	0.26
Plasma glucose (mmol l ⁻¹)	6.5 ± 0.1	7.1 ± 0.9	6.8 ± 0.5	6.6 ± 0.1	6.7 ± 0.7	7.1 ± 0.3	6.6 ± 0.1	6.8 ± 0.6	6.7 ± 0.6	0.79	0.39	0.17
Glucose extraction eff. (%)	4.6 ± 0.5	5.2 ± 0.9	3.8 ± 0.6	6.0 ± 0.6	8.9 ± 0.8	6.7 ± 1.3	11.2 ± 1.0	10.7 ± 1.9	9.2 ± 1.4	0.29	<0.01	0.47
Glucose O ₂ quotient	0.78 ± 0.14	0.94 ± 0.18	0.72 ± 0.19	1.04 ± 0.05	1.29 ± 0.16	1.15 ± 0.36	1.64 ± 0.08	1.54 ± 0.28	1.56 ± 0.27	0.79	<0.01	0.79
G + L O ₂ quotient	0.55 ± 0.11	0.73 ± 0.15	0.45 ± 0.16	0.83 ± 0.02	1.01 ± 0.17	0.92 ± 0.33	1.43 ± 0.05	1.32 ± 0.28	1.27 ± 0.26	0.71	<0.01	0.81

Data are presented as the mean ± SEM for 7 control lambs, 5 IUGR lambs and 5 IUGR-AR lambs. P values for the ANOVA analysis on group (G), insulin infusion rate (study period, P) and the interaction (group × infusion rate; I) are present. Glucose extraction eff., glucose extraction efficiency; G + L, glucose + lactate.

Data are presented as the mean ± SEM for 7 control lambs, 5 IUGR lambs and 5 IUGR-AR lambs. P values for the ANOVA analysis on group (G), insulin infusion rate (study period, P) and the interaction (group × infusion rate; I) are present. Glucose extraction eff., glucose extraction efficiency; G + L, glucose + lactate.

Hindlimb glucose utilization rates were not different between IUGR and IUGR-AR lambs (28.4 ± 2.9 and $28.6 \pm 3.0 \mu\text{mol min}^{-1} \text{kg}^{-1}$, respectively), but hindlimb glucose utilization rates in both experimental groups were greater ($P < 0.05$) than control lambs ($19.8 \pm 2.5 \mu\text{mol min}^{-1} \text{kg}^{-1}$), regardless of the insulin infusion rate (Fig. 6A). Across all groups, hindlimb glucose utilization rates increased from basal ($18.9 \pm 1.9 \mu\text{mol min}^{-1} \text{kg}^{-1}$) to hyperinsulinaemic periods when insulin was infused at $2 \text{ mU min}^{-1} \text{kg}^{-1}$ ($25.9 \pm 1.9 \mu\text{mol min}^{-1} \text{kg}^{-1}$) and $4 \text{ mU min}^{-1} \text{kg}^{-1}$ ($32.0 \pm 3.0 \mu\text{mol min}^{-1} \text{kg}^{-1}$). This coincided with greater glucose extraction efficiencies ($4.5 \pm 0.6\%$, $7.1 \pm 0.6\%$ and $10.4 \pm 0.6\%$ at basal, and 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$, respectively) and glucose oxygen quotients (0.81 ± 0.11 , 1.13 ± 0.11 and 1.59 ± 0.11 at basal, and 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$, respectively; Table 3). Glucose extraction efficiencies, glucose oxygen quotients, and glucose + lactate oxygen quotients were not different among groups. However, glucose + lactate oxygen quotient increased sequentially with higher insulin infusion rates (0.58 ± 0.10 , 0.89 ± 0.11 , 1.34 ± 0.11 at 0, 2 and 4 $\text{mU min}^{-1} \text{kg}^{-1}$). Hindlimb glucose oxidation rates increased from basal ($1.2 \pm 0.4 \mu\text{mol min}^{-1} \text{kg}^{-1}$) to subsequent periods when insulin was infused at 4 $\text{mU min}^{-1} \text{kg}^{-1}$ ($4.9 \pm 0.4 \mu\text{mol min}^{-1} \text{kg}^{-1}$), but were not different among groups during basal or hyperinsulinaemic periods (Fig. 6B). However, hindlimb fractional glucose oxidation rates were lower in IUGR lambs ($10.5 \pm 1.4\%$) and IUGR-AR lambs ($9.7 \pm 1.4\%$) than in control lambs ($16.6 \pm 1.2\%$) regardless of insulin infusion rate (Fig. 6C). In all groups, fractional glucose oxidation rates increased from basal ($6.7 \pm 1.0\%$) to subsequent higher insulin infusion rates ($17.9 \pm 1.0\%$).

Post-mortem organ weights

At necropsy body weight and brain, lung, liver, kidney, heart, left ventricle, right ventricle and hindlimb weights were less in IUGR and IUGR-AR lambs compared to controls (Table 4). Brain and liver weights relative to body weights were greater in IUGR and IUGR-AR lambs compared to control lambs. Lung, kidney and right ventricle weights relative to body weight were not different among groups. Heart weight relative to body weight was greater in IUGR-AR lambs than in IUGR and control lambs, and relative left ventricle weight was greater in IUGR-AR lambs than controls.

In vitro pancreatic islet insulin secretion

Pancreatic islet viability assessed by OCR/DNA was not different between control ($387 \pm 23 \text{ nmol O}_2 \text{ min}^{-1} \text{ (mg$

DNA)⁻¹) and IUGR lambs ($396 \pm 43 \text{ nmol O}_2 \text{ min}^{-1} (\text{mg DNA})^{-1}$). Islets from IUGR and IUGR-AR lambs had reduced first-phase and second-phase GSIS compared to islets from control lambs (Fig. 7). IUGR and IUGR-AR GSIS response was similar. Islets from IUGR lambs also had less insulin content compared to control islets, but IUGR-AR islets were not different among groups.

Ex vivo skeletal glucose oxidation rates

There was an interaction ($P < 0.05$) between experimental groups and incubation media for *ex vivo* glucose oxidation rates in primary myofibres. Glucose oxidation rates of muscle fibres from control lambs were $25 \pm 5 \text{ pmol mg}^{-1} \text{ h}^{-1}$ greater in media with insulin compared to basal media without insulin (Fig. 8). Inclusion of cytochalasin B (glucose transport inhibitor) or catecholamines to insulin-supplemented media decreased insulin-stimulated glucose oxidation rates in muscle fibres from controls to rates that were below those observed in basal media. Glucose oxidation rates in basal media were not different between IUGR and IUGR-AR muscle fibres but were lower in both of these groups compared to control muscle. Insulin-stimulated glucose oxidation rates were not different between IUGR and IUGR-AR muscle fibres but were 33 ± 6 and $27 \pm 8 \text{ pmol mg}^{-1} \text{ h}^{-1}$ lower, respectively, compared to control muscle fibres. Moreover, insulin-supplemented media had no effect on glucose oxidation rates in IUGR muscle fibres when compared to rates in basal media, but insulin increased glucose

oxidation rates $18 \pm 7 \text{ pmol mg}^{-1} \text{ h}^{-1}$ above basal rates in IUGR-AR muscle fibres. Inclusion of cytochalasin B or catecholamines in insulin-supplemented media reduced glucose oxidation rates in IUGR and IUGR-AR muscle fibres to rates that were not different from those observed in basal media.

Skeletal muscle glycogen content and citrate synthase activity

Glycogen content in the semitendinosus muscle was not different among control ($13.7 \pm 1.2 \text{ mg g}^{-1}$), IUGR ($15.3 \pm 1.1 \text{ mg g}^{-1}$) and IUGR-AR ($11.9 \pm 1.2 \text{ mg g}^{-1}$) groups. Citrate synthase activities were not different between semitendinosus muscles from control ($343 \pm 13 \text{ } \mu\text{mol min}^{-1} (\text{mg protein})^{-1}$) and IUGR lambs ($348 \pm 12 \text{ } \mu\text{mol min}^{-1} (\text{mg protein})^{-1}$) but were lower ($P < 0.05$) in IUGR-AR lambs ($287 \pm 15 \text{ } \mu\text{mol min}^{-1} (\text{mg protein})^{-1}$) compared to control or IUGR lambs.

Glucose transporters, insulin receptor and ADR β 2 in muscle

GLUT1 concentrations in the semitendinosus muscle were not different between control and IUGR lambs or between IUGR and IUGR-AR lambs but were greater ($P < 0.05$) in IUGR-AR lambs compared to control lambs (Fig. 9A). GLUT4 concentrations were lower ($P < 0.05$) in the semitendinosus muscle from IUGR and IUGR-AR lambs than in control lambs (Fig. 9B). Protein concentrations




Figure 6. Hindlimb glucose fluxes

Hindlimb weight-specific net glucose utilization rates (A), glucose oxidation rates (B) and fractional glucose oxidation (C) were measured in control ($n = 7$; 3M/4F), IUGR ($n = 5$; 1M/4F) and IUGR-AR ($n = 5$; 1M/4F) lambs. Rates of glucose utilization across the hindlimb were determined at three steady-state periods: basal ($0 \text{ mU min}^{-1} \text{ kg}^{-1}$) and two hyperinsulinaemic periods produced with insulin infusion rates at 2 and $4 \text{ mU min}^{-1} \text{ kg}^{-1}$ (x-axis). Glucose oxidation and fractional glucose oxidation rates were evaluated at basal and $4 \text{ mU min}^{-1} \text{ kg}^{-1}$ infusion periods. Main effects in the two-way ANOVA included experimental group, study period for the insulin infusion rate and their interaction (group by period). P values are presented on the graph if the effects were significant ($P \leq 0.05$).

Table 4. Post-mortem organ weights

Group (n)	Control (15)	IUGR (14)	IUGR-AR (7)
Body weight (kg)	13.1 ± 0.6 ^a	8.9 ± 0.6 ^b	7.3 ± 0.8 ^b
Brain (g)	73 ± 2 ^a	64 ± 2 ^b	62 ± 3 ^b
Lung (g)	229 ± 11 ^a	163 ± 12 ^b	127 ± 16 ^b
Liver (g)	342 ± 15 ^a	251 ± 15 ^b	225 ± 21 ^b
Average kidney (g)	40.3 ± 1.8 ^a	30.3 ± 1.8 ^b	25.6 ± 2.6 ^b
Heart (g)	82 ± 4 ^a	56 ± 4 ^b	56 ± 6 ^b
Right ventricle (g)	17.8 ± 1.0 ^a	11.7 ± 1.0 ^b	10.2 ± 1.4 ^b
Left ventricle (g)	30.9 ± 1.7 ^a	22.3 ± 1.9 ^b	20.6 ± 2.5 ^b
Hindlimb (kg)	1.20 ± 0.06 ^a	0.80 ± 0.05 ^b	0.68 ± 0.08 ^b
Relative brain weight (g kg ⁻¹) [†]	5.6 ± 0.5 ^a	7.8 ± 0.5 ^b	9.6 ± 0.8 ^b
Relative lung weight (g kg ⁻¹) [†]	17.5 ± 0.7	18.8 ± 0.7	18.0 ± 1.0
Relative liver weight (g kg ⁻¹) [†]	26.1 ± 0.9 ^a	29.0 ± 0.9 ^b	31.7 ± 1.3 ^b
Relative kidney weight (g kg ⁻¹) [†]	3.1 ± 0.2	3.5 ± 0.2	3.8 ± 0.3
Relative heart weight (g kg ⁻¹) [†]	6.2 ± 0.2 ^a	6.3 ± 0.2 ^a	7.8 ± 0.3 ^b
Relative left ventricle weight (g kg ⁻¹) [†]	2.4 ± 0.1 ^a	2.6 ± 0.1 ^{ab}	2.8 ± 0.2 ^b
Relative right ventricle weight (g kg ⁻¹) [†]	1.4 ± 0.1	1.3 ± 0.1	1.4 ± 0.1

Data are expressed as the mean ± SEM. Differences ($P < 0.05$) between groups are identified with different superscript letters.

[†]Relative to body weight.

for ADR β 2 and INSR were not different among groups (Fig. 9C and D).

Discussion

Previous work has shown that IUGR fetal sheep produced by placental insufficiency develop disparities in insulin secretion, skeletal muscle growth and glucose metabolism in late gestation (Limesand *et al.* 2006, 2007; Brown *et al.* 2015; Yates *et al.* 2016). In this study, we show that the disruption in pancreatic islet insulin secretion and skeletal muscle glucose metabolism persisted in 1-month-old lambs that were born following placental insufficiency-induced IUGR, despite normal whole-body glucose utilization rates and insulin sensitivity. Specifically, we found that GSIS, which is enhanced in IUGR lambs at earlier ages (Camacho *et al.* 2017), was reduced at 1 month of age despite normal plasma catecholamine concentrations at this age. Reductions in insulin secretion responsiveness in IUGR lambs were associated with less islet insulin content, which indicates a diminished capacity for their β -cells to synthesize and store insulin, similar to the IUGR fetus (Limesand *et al.* 2006). Additionally, the IUGR hindlimb glucose utilization rates were higher than normal but the fractional glucose oxidation rates were lower. Studies in primary muscle fibres from IUGR lambs further showed that the muscle-specific glucose oxidative capacity was impaired. Postnatal manipulation of β adrenergic receptor activity via daily oral treatment with ADR β 2 agonist and ADR β 1/ β 3 antagonists improved whole-body glucose utilization rates and basal insulin sensitivity in IUGR lambs. However, the treatment had no effect on their hindlimb glucose metabolism or

skeletal muscle glucose oxidation rates. This coincided with equivalent skeletal muscle expression of ADR β 2 and insulin receptor β among all groups. Unexpectedly, IUGR lambs also had faster heart rates that were independent of ADR β 1 activation because postnatal ADR β 1 antagonists did not slow heart rates in IUGR-AR lambs. The findings from this study show that changes in β adrenergic activity underlie some but not all postnatal outcomes of IUGR produced by placental insufficiency and that multiple mechanisms contribute to the programming of metabolic dysfunction in the IUGR lambs.

Neonatal growth

At birth, IUGR lambs weighed less than controls and had asymmetric fetal growth restriction, which is consistent with fetal growth patterns and birth metrics for pathological IUGR human infants (Riyami *et al.* 2011). IUGR lambs had greater head circumference-to-birth weight ratios that indicate fetal brain sparing, which was confirmed at necropsy. This asymmetry was comparable to the ovine endometrial carunclectomy model of placental restriction (De Blasio *et al.* 2006, 2007; Owens *et al.* 2007*bb*; Morrison, 2008; Liu *et al.* 2015). We attribute the asymmetric growth in our IUGR lambs to the progressive rise in circulating fetal catecholamines brought on by placental insufficiency-induced hypoxaemia and hypoglycaemia (Macko *et al.* 2013, 2016; Davis *et al.* 2015). Although not measured in the present study, it is reasonable to assume that our IUGR lambs were exposed to chronically elevated concentrations of catecholamines *in utero*, as shown previously (Limesand *et al.* 2006, 2013).

Infants with fetal growth restriction typically exhibit accelerated early-life growth velocity, which independently predicts their risk for developing metabolic disease (Barker *et al.* 2002; Dulloo, 2006; Claris *et al.* 2010). Driven by greater fat deposition, early catch-up growth is associated with greater central obesity, insulin resistance and cardiovascular disease in humans (Jaquet *et al.* 2000; Gluckman *et al.* 2008; Ibanez *et al.* 2008). In other sheep models of IUGR, longitudinal studies show that IUGR lambs reach normal body weights by 1 month of age (De Blasio *et al.* 2006; Liu *et al.* 2015; Spiroski *et al.* 2018). However, greater central adiposity at 6 weeks of age indicates that a larger percentage of their early weight gain is due to fat deposition, even though body composition normalized in adulthood (Liu *et al.* 2015). Similarly, the over-nourished adolescent model of IUGR exhibited greater daily weight gain and adiposity near weaning, but their body composition normalized later (Wallace *et al.* 2018; Wallace, 2019). Unlike the other ovine models, our IUGR lambs had similar fractional growth rates through

the first 30 days. The reason for the absence of catch-up growth is not clear, but it is unlikely that it was due to insufficient postnatal nutrition. After colostrum, all lambs were fed similar amounts of commercial milk replacer to minimize nutrient variability from heat stressed ewes (Abdalla *et al.* 1993). The average daily gain for our control lambs was comparable to those reported in lambs reared by the ewe (Louey *et al.* 2000; De Blasio *et al.* 2006; Liu *et al.* 2015; Wallace *et al.* 2018). The lack of early-stage catch-up growth is in fact a major benefit of this model and study because early catch-up growth may contribute to metabolic deficits in some cases. Here we demonstrate that metabolic deficits can occur in the absence of confounding early catch-up growth. Therefore, despite the absence of confounding catch-up growth in our IUGR lambs, defects in β -cell function and skeletal muscle glucose metabolism were apparent, which reflect developmental programming due to the *in utero* environment.

The lack of improved growth performance in IUGR lambs treated with clenbuterol was unexpected based




Figure 7. Isolated islet insulin secretion responsiveness to glucose

Dynamic measurements of glucose-stimulated insulin secretion were analysed in islets isolated from control ($n = 4$; 2M/2F), IUGR ($n = 3$; 1M/2F) and IUGR-AR ($n = 3$; 0M/3F) lambs. A, insulin secretion rates ($\text{pg min}^{-1} (\mu\text{g DNA})^{-1}$) are shown at the time collected. Stimulatory glucose concentrations (11.1 mmol l^{-1}) were initiated at 3 min, which is indicated by the grey arrow. B, area under the curve (AUC) for 3–11 min was calculated for each experimental group to measure first-phase insulin secretion. C, AUCs for second-phase insulin secretion (12–40 min) are presented. D, islet insulin contents were measured. Differences ($P < 0.05$) between experimental groups are indicated by different letters.

on previous findings in older lambs (Beermann *et al.* 1987; Bohorov *et al.* 1987). Beermann (2002) postulated that this unresponsiveness to an ADR β 2 agonist in young lambs is caused by either low skeletal muscle sensitivity to ADR β 2 or the growth rate is already near the maximum for skeletal muscle at this age. Our findings are inconsistent with ADR β 2 insensitivity because we found greater whole-body glucose utilization rates and insulin sensitivity in IUGR-AR lambs. However, if the latter is true and muscle growth is near maximum, repartitioning of nutrients with ADR β 2 would not be effective. Furthermore, younger, less physiologically mature animals have lower rates of lipid accretion than mature animals, which also lowers ADR β 2 agonist effectiveness (Williams *et al.* 1987; Maltin *et al.* 1990). Alternatively, the growth rates exhibited in our IUGR lambs may be indicative of a lower capacity for muscle accretion, as previously observed (Yates *et al.* 2014, 2016; Soto *et al.* 2017).

Insulin secretion

At 1 month of age, IUGR lambs exhibited substantially impaired first- and second-phase GSIS. Concurrent deficits in both phases of secretion are indicative of glucose intolerance, which frequently progresses with age to a diabetic state that is characterized by complete loss of the first-phase secretion and further decline of the second-phase secretion (Gerich, 2002; Seino *et al.* 2011). Lower GSIS by 1 month of age is a stark difference to the

compensatory enhancement of GSIS that we previously observed in IUGR lambs at 1 week of age. In fetal sheep, placental insufficiency is associated with lower insulin secretion as early as 0.7 of gestation, which is prior to the onset of fetal growth restriction (Limesand *et al.* 2013; Macko *et al.* 2013). Blunted insulin secretion continues throughout the remainder of gestation and is inhibited in part by high concentrations of plasma catecholamines (Owens *et al.* 2007a; Leos *et al.* 2010; Macko *et al.* 2016). In fact, similar inhibition occurred when hypercatecholaminaemia was induced in normally grown fetuses with an exogenous noradrenaline infusion (Chen *et al.* 2014), acute maternofetal hypoxia (Jackson *et al.* 2000; Yates *et al.* 2012b), anaemic hypoxaemia (Benjamin *et al.* 2017), or insulin imbalance (Andrews *et al.* 2015). Interestingly, an acute adrenergic blockade in the IUGR fetus revealed the development of this hyper-insulin secretion response (Leos *et al.* 2010; Macko *et al.* 2013). This compensatory enhancement of insulin secretion develops in opposition to chronic adrenergic stimulation, because we also observed hypersecretion in fetal sheep immediately after stopping a week-long infusion of noradrenaline that was still present 5 days after the infusion was terminated (Chen *et al.* 2014, 2017). Primary islets from noradrenaline-infused fetuses exhibited greater GSIS *in vitro*. These islets had normal insulin content, calcium signalling and morphology but showed evidence of adrenergic desensitization, which now appears to be the mechanism for compensatory insulin stimulus–secretion coupling (Chen *et al.* 2017; Kelly *et al.* 2018). Additionally, GSIS remained augmented in placental insufficiency-induced, overnourished adolescent-induced and twinning-induced IUGR lambs for more than a week after birth (Gatford *et al.* 2013; Camacho *et al.* 2017; Wallace *et al.* 2018), which helps to explain the dangerous condition of transitional hyperinsulinaemic hypoglycaemia that frequently afflicts newborns with IUGR (Stanley *et al.* 2015; Rozance & Hay, 2016).

Our study shows that the compensatory enhancement of insulin secretion is a transient condition that subsides after the first few weeks of life to reveal programmed deficits in β -cell function. Perfusion studies recapitulate the poor insulin secretion response of IUGR islets to glucose, demonstrating that the impairment is intrinsic to the β -cells. In addition to lower insulin secretion responsiveness, the capacity of the IUGR islets to synthesize and store insulin was reduced, a deficiency that was shown previously in fetal sheep with placental insufficiency-induced IUGR (Limesand *et al.* 2006). Although adrenergic dysregulation was shown to affect fetal islets with IUGR, daily administration of ADR β modifiers did not improve islet response to glucose in IUGR lambs. However, there was a modest recovery in islet insulin content, which may reflect lower insulin demands due to the improved insulin sensitivity in IUGR-AR lambs




Figure 8. Ex vivo glucose oxidation rates in skeletal muscle

Glucose oxidation rates were measured in semitendinosus muscle fibres from control ($n = 12$; 8M/4F), IUGR ($n = 13$; 3M/10F) and IUGR-AR ($n = 6$; 1M/5F) lambs. Rates of glucose oxidation were determined in four media conditions containing no hormones (basal), $10 \mu\text{U ml}^{-1}$ insulin, insulin ($10 \mu\text{U ml}^{-1}$) + catecholamines ($12.5 \mu\text{mol l}^{-1}$ adrenaline and $12.5 \mu\text{mol l}^{-1}$ noradrenaline) and insulin ($10 \mu\text{U ml}^{-1}$) + 20 mmol l^{-1} cytochalasin B. Differences ($P \leq 0.05$) are identified by different letters above the bars (means \pm SEM).

(Leos *et al.* 2010; Kelly *et al.* 2018). These findings show that pancreatic islet dysfunction persists after birth due to limited insulin production and storage in IUGR islets, even though there is hyper-insulin secretion at earlier ages.

Insulin action on tissues

Whole-body glucose utilization rates were similar between control and IUGR lambs. Thus, data from both groups were pooled to construct dose–response curves for insulin-stimulated glucose utilization, which were used to identify half-maximal insulin sensitivity (ED_{50}) and maximum insulin responsiveness as previously described (Kahn, 1978). Half-maximal insulin sensitivity at 1 month of age was comparable to that observed in non-pregnant adult ewes (Bergman *et al.* 1989; Petterson *et al.* 1993). Although neonatal ED_{50} was similar to adult ewes, maximum insulin responsiveness was about fourfold greater in lambs, which is consistent with the previously observed progressive decline in insulin action as sheep advance in age (Gatford *et al.* 2004).

We previously found that whole-body glucose utilization rates were greater in IUGR lambs at 2 weeks of age (Camacho *et al.* 2017). In this study, similar

whole-body glucose utilization rates between control and IUGR lambs indicate that a correction in whole-body insulin action for glucose occurs by 1 month of age. Furthermore, hepatic glucose production rates did not differ between control and IUGR lambs at 2 weeks (Camacho *et al.* 2017) or 1 month of age, even though plasma lactate concentrations were higher in IUGR lambs at both ages. The correction in whole-body insulin action was not explained by hindlimb glucose fluxes or skeletal muscle glucose transporter profiles. Hindlimb glucose utilization rates were greater in IUGR lambs under basal and hyperinsulinaemic conditions, despite less GLUT4 and similar GLUT1 concentrations in skeletal muscle. Interestingly, there was no difference in GLUT1 or GLUT4 concentrations between control and IUGR skeletal muscle near term (Limesand *et al.* 2007) or at 2 weeks of age (Camacho *et al.* 2017). Therefore, muscle adaptations responsible for increased insulin sensitivity appear to be independent of the expression of these glucose transporters, but could involve the translocation of GLUT4 to the plasma membrane. Furthermore, these data indicate that compensatory changes in glucose uptake by other tissues might help to normalize glucose tolerance in IUGR lambs. These findings show continuing changes in glucose




Figure 9. Glucose transporters, insulin receptor and adrenergic receptor $\beta 2$ expression in skeletal muscle

Protein expression levels of GLUT1 (A), GLUT4 (B), ADR $\beta 2$ (ADRB2; C) and insulin receptor β (INSR; D) were measured in semitendinosus muscle from control ($n = 8$; 4M/4F), IUGR ($n = 8$; 3M/5F) and IUGR-AR ($n = 7$; 1M/6F) lambs. Representative images of western blots are shown for the glucose transporters and receptors and β -Tubulin (TUBB), which was used for normalization. Means \pm SEM are presented in the bar graphs and differences ($P < 0.05$) are indicated with different letters.

metabolism of IUGR lambs over the first month of life, although it is unclear whether changes in insulin sensitivity will ultimately progress into glucose intolerance as in other models (Ford *et al.* 2007; Owens *et al.* 2007b).

Whole-body insulin sensitivity and glucose utilization rates were greater in IUGR lambs treated with β adrenergic modifiers. Across all insulin concentrations, whole-body glucose utilization rates were $\sim 23\%$ higher in IUGR-AR lambs compared to both control and IUGR lambs. This coincided with greater hindlimb-specific glucose utilization rates and skeletal muscle GLUT1 concentrations compared to control lambs. However, neither glucose utilization rates nor GLUT1 concentrations differed from untreated IUGR lambs, which indicates contributions from other mechanisms. In adult humans and rats, chronic administration of ADR β 2 agonists increased insulin sensitivity for non-oxidative glucose utilization and lactate production but not glycogen synthesis (Scheidegger *et al.* 1984; Budohoski *et al.* 1987; Jensen *et al.* 2005). A subsequent study of post-receptor interactions between insulin and β adrenergic signalling pathways via acute *ex vivo* treatments found that protein kinase A and protein kinase B (AKT) regulate distinct pools of glycogen synthase kinase-3 α/β that are separated by locale within the cell or by the niche of co-activators (Jensen *et al.* 2007). We previously found that co-incubation of rat soleus with insulin and ADR β 2 agonist for 1 h had an additive effect on AKT phosphorylation, although ADR β 2 agonist in the absence of insulin had no effect on AKT phosphorylation and in fact lowered glucose uptake (Cadaret *et al.* 2017). Additive post-receptor effects may help to explain differences in acute *ex vivo* insulin-stimulated glucose oxidation, but reduced citrate synthase activity associated with β adrenergic modifiers in our IUGR lambs indicate potentially reduced mitochondrial density and other detrimental metabolic changes.

Fractional glucose oxidation rates are lower in IUGR fetal sheep near term (Limesand *et al.* 2007; Brown *et al.* 2015), which we have postulated is due to skeletal muscle-specific programming aimed at nutrient sparing (Yates *et al.* 2012a, 2018). In this study, we found that impaired glucose oxidative capacity was indeed muscle-specific and persisted in IUGR lambs at 1 month of age, but was not improved by postnatal β adrenergic modifiers. Hindlimb-specific glucose utilization rates in IUGR lambs were greater than normal across a range of insulin concentrations, but the proportion of glucose utilized by hindlimb tissues for oxidation was diminished. Moreover, primary hindlimb skeletal muscle had lower *ex vivo* glucose oxidation rates under basal and insulin-stimulated incubation conditions. These results demonstrate that insulin sensitivities for non-oxidative and oxidative glucose metabolism differ in skeletal muscle of IUGR lambs similar to whole-body glucose metabolism

in the IUGR fetus (Limesand *et al.* 2007; Brown *et al.* 2015). For IUGR fetuses, this could be at least partially explained by enhanced insulin signalling pathways, as IUGR fetal muscle expresses greater insulin receptor β and less p85 α (Thorn *et al.* 2009). In IUGR lambs, however, skeletal muscle insulin receptor β concentrations were not affected at 2 weeks (Camacho *et al.* 2017) or 1 month of age (present study). Moreover, normal skeletal muscle citrate synthase activity in IUGR lambs indicates that diminished oxidative metabolic capacity is not due to reduced mitochondrial density. Rather, it may be due to altered pyruvate metabolism or impaired mitochondrial oxidative phosphorylation, as suggested by previous studies (Brown *et al.* 2015; Kelly *et al.* 2017; Pendleton *et al.* 2019). Equivalent lactate output, nutrient quotients and skeletal muscle glycogen content among all of our lambs indicates that the lower fractional glucose oxidation was not offset by greater glycolytic rates and glucose storage. Hindlimb glucose and lactate fluxes in IUGR fetal sheep further indicate that faster glycolytic rates are not a component of IUGR skeletal muscle programming (Rozance *et al.* 2018). Thus, additional studies will be needed to characterize the mechanisms responsible for the programmed defects in skeletal muscle glucose metabolism demonstrated by this study.

Cardiovascular response

The chief aim of measuring the cardiovascular response in the present study was to determine the *in vivo* functional presence of the orally administered ADR β modifiers. ADR β 1 agonist dobutamine increased the heart rate in both control and IUGR group, albeit to a lesser extent, but was unable to produce any change in the heart rate of the lambs in IUGR-AR group. This demonstrates the functional presence of orally administered ADR β 1 antagonist atenolol. Unexpectedly, the treatment of ADR β modifiers increased the relative size of the heart, specifically the left ventricle, which may indicate that the hypertrophy was from direct adrenergic regulation or from indirect adrenergic alteration of systemic blood pressures. The direct adrenergic mechanism may be in response to ADR β 2 activation and ADR β 1 inhibition to lower cardiomyocyte apoptosis via phosphoinositide 3 kinase and AKT pathways (Communal *et al.* 1999; Chesley *et al.* 2000; Gu *et al.* 2000; Zaugg *et al.* 2000; Zhu *et al.* 2001). In humans, IUGR is associated with greater risk for cardiovascular pathologies including hypertension, tachycardia and irregular cardiac growth (Brodzski *et al.* 2005; Crispi *et al.* 2010; Zanardo *et al.* 2011; Spence *et al.* 2012; Bjarnegard *et al.* 2013; Gaillard *et al.* 2013; Chatmethakul & Roghair, 2019). From this experiment, we show that heart rates were faster in IUGR lambs irrespective of the postnatal treatment and that the hearts from IUGR lambs were less responsive to the ADR β 1 agonist dobutamine.

These findings warrant further investigation of ADR β 1 responsiveness and other factors regulating heart rate.

Conclusion

Present findings allow us to conclude that metabolic pathologies in offspring that were born with IUGR manifest very early after birth and are the product of adaptive programming involving multiple tissues. Enhanced insulin secretion responsiveness to glucose is present in IUGR lambs at 1 week of age but subsides by 4 weeks of age, at which time β -cell dysfunction is apparent. Whole-body insulin sensitivity, which is also greater in the near-term IUGR fetus and lamb at 2 weeks of age, had normalized by 1 month of age. However, disparities in skeletal muscle-specific glucose metabolism persisted in lambs with IUGR. These include higher hindlimb glucose utilization rates that may be required to compensate for oxidative deficiencies of glucose in primary IUGR myocytes, thus causing fractional glucose oxidation rates to be lower in the hindlimb. Although the inherent discrepancies between glucose uptake and oxidation in muscle were unresolved by lactate release and glycogen content, greater transamination of pyruvate to alanine has been described in muscle of the IUGR fetus, which, if persistent, may explain the deficiencies in carbohydrate metabolism (Chang *et al.* 2019). Alternatively, the myocyte deficiencies in insulin-stimulated glucose oxidation indicate that other factors contribute to glucose metabolism *in vivo*. We postulated that disrupted β adrenergic signalling plays an underlying role in the development of metabolic defects based on previously observed chronic hypercatecholaminaemia in the IUGR fetus. However, daily oral supplementation of pharmaceuticals intended to target suspected β adrenergic changes resulted in only modest improvements in insulin-sensitive glucose metabolism and did not improve deficits in islet GSIS or skeletal muscle glucose metabolism in IUGR lambs. Moreover, targeted β adrenergic modifications did not improve the increased basal heart rates observed in IUGR lambs. Together, this study provides new insights regarding β -cell dysfunction and muscle-specific adaptations that predispose neonates that were born with IUGR to later life metabolic dysfunction.

References

- Abdalla EB, Kotby EA & Johnson HD (1993). Physiological responses to heat-induced hyperthermia of pregnant and lactating ewes. *Small Ruminant Res* **11**, 125–134.
- Andrews SE, Brown LD, Thorn SR, Limesand SW, Davis M, Hay WW Jr & Rozance PJ (2015). Increased adrenergic signaling is responsible for decreased glucose-stimulated insulin secretion in the chronically hyperinsulinemic ovine fetus. *Endocrinology* **156**, 367–376.
- Baltensperger K, Karoor V, Paul H, Ruoho A, Czech MP & Malbon CC (1996). The beta-adrenergic receptor is a substrate for the insulin receptor tyrosine kinase. *J Biol Chem* **271**, 1061–1064.
- Barker DJ (1990). The fetal and infant origins of adult disease. *BMJ* **301**, 1111.
- Barker DJ (1993). Fetal origins of coronary heart disease. *Br Heart J* **69**, 195–196.
- Barker DJ (2002). Fetal programming of coronary heart disease. *Trends Endocrinol Metab* **13**, 364–368.
- Barker DJ, Eriksson JG, Forsen T & Osmond C (2002). Fetal origins of adult disease: strength of effects and biological basis. *Int J Epidemiol* **31**, 1235–1239.
- Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA & Robinson JS (1993a). Fetal nutrition and cardiovascular disease in adult life. *Lancet* **341**, 938–941.
- Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K & Clark PM (1993b). Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. *Diabetologia* **36**, 62–67.
- Barker DJ, Osmond C, Forsen TJ, Kajantie E & Eriksson JG (2005). Trajectories of growth among children who have coronary events as adults. *N Engl J Med* **353**, 1802–1809.
- Barker DJ, Osmond C, Forsen TJ, Kajantie E & Eriksson JG (2007). Maternal and social origins of hypertension. *Hypertension* **50**, 565–571.
- Bassett JM, Weeding CM & Hanson C (1990). Desensitization of beta-receptor mediated responses to epinephrine in fetal lambs by prolonged ritodrine administration. *Pediatr Res* **28**, 388–393.
- Bazaes RA, Alegria A, Pittaluga E, Avila A, Iniguez G & Mericq V (2004). Determinants of insulin sensitivity and secretion in very-low-birth-weight children. *J Clin Endocrinol Metab* **89**, 1267–1272.
- Beermann DH (2002). Beta-adrenergic receptor agonist modulation of skeletal muscle growth. *J Anim Sci* **80**, E18–E23.
- Beermann DH, Butler WR, Hogue DE, Fishell VK, Dalrymple RH, Ricks CA & Scanes CG (1987). Cimaterol-induced muscle hypertrophy and altered endocrine status in lambs. *J Anim Sci* **65**, 1514–1524.
- Benjamin JS, Culpepper CB, Brown LD, Wesolowski SR, Jonker SS, Davis MA, Limesand SW, Wilkening RB, Hay WW Jr & Rozance PJ (2017). Chronic anemic hypoxemia attenuates glucose-stimulated insulin secretion in fetal sheep. *Am J Physiol Regul Integr Comp Physiol* **312**, R492–R500.
- Bergman EN, Reulein SS & Corlett RE (1989). Effects of obesity on insulin sensitivity and responsiveness in sheep. *Am J Physiol* **257**, E772–E781.
- Bjarnegard N, Morsing E, Cinthio M, Lanne T & Brodzski J (2013). Cardiovascular function in adulthood following intrauterine growth restriction with abnormal fetal blood flow. *Ultrasound Obstet Gynecol* **41**, 177–184.
- Bocking AD, White SE, Kent S, Fraher L, Han VK, Rundle H & Hooper SB (1995). Effect of prolonged catecholamine infusion on heart rate, blood pressure, breathing, and growth in fetal sheep. *Can J Physiol Pharmacol* **73**, 1750–1758.

- Bohorov O, Buttery PJ, Correia JH & Soar JB (1987). The effect of the beta-2-adrenergic agonist clenbuterol or implantation with oestradiol plus trenbolone acetate on protein metabolism in wether lambs. *Br J Nutr* **57**, 99–107.
- Brennesvik EO, Ktori C, Ruzzin J, Jebens E, Shepherd PR & Jensen J (2005). Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. *Cell Signal* **17**, 1551–1559.
- Brodzski J, Lanne T, Marsal K & Ley D (2005). Impaired vascular growth in late adolescence after intrauterine growth restriction. *Circulation* **111**, 2623–2628.
- Brown LD, Rozance PJ, Bruce JL, Friedman JE, Hay WW Jr & Wesolowski SR (2015). Limited capacity for glucose oxidation in fetal sheep with intrauterine growth restriction. *Am J Physiol Regul Integr Comp Physiol* **309**, R920–R928.
- Budohoski L, Challiss RA, Dubaniewicz A, Kaciuba-Uscilko H, Leighton B, Lozeman FJ, Nazar K, Newsholme EA & Porta S (1987). Effects of prolonged elevation of plasma adrenaline concentration in vivo on insulin-sensitivity in soleus muscle of the rat. *Biochem J* **244**, 655–660.
- Byrem TM, Beermann DH & Robinson TF (1998). The beta-agonist cimaterol directly enhances chronic protein accretion in skeletal muscle. *J Anim Sci* **76**, 988–998.
- Cadaret CN, Beede KA, Riley HE & Yates DT (2017). Acute exposure of primary rat soleus muscle to zilpaterol HCl (beta2 adrenergic agonist), TNFalpha, or IL-6 in culture increases glucose oxidation rates independent of the impact on insulin signaling or glucose uptake. *Cytokine* **96**, 107–113.
- Camacho LE, Chen X, Hay WW Jr & Limesand SW (2017). Enhanced insulin secretion and insulin sensitivity in young lambs with placental insufficiency-induced intrauterine growth restriction. *Am J Physiol Regul Integr Comp Physiol* **313**, R101–R109.
- Castle A, Yaspelkis BB 3rd, Kuo CH & Ivy JL (2001). Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions. *Life Sci* **69**, 599–611.
- Chang EI, Wesolowski SR, Gilje EA, Baker PR 2nd, Reis JA, D'Alessandro A, Hay WW Jr, Rozance PJ & Brown LD (2019). Skeletal muscle amino acid uptake is lower and alanine production is greater in late gestation intrauterine growth restricted fetal sheep hindlimb. *Am J Physiol Regul Integr Comp Physiol* **317**, R615–R629.
- Chatmethakul T & Roghair RD (2019). Risk of hypertension following perinatal adversity: IUGR and prematurity. *J Endocrinol* **242**, T21–T32.
- Chen X, Fahy AL, Green AS, Anderson MJ, Rhoads RP & Limesand SW (2010). β_2 -Adrenergic receptor desensitization in perirenal adipose tissue in fetuses and lambs with placental insufficiency-induced intrauterine growth restriction. *J Physiol* **588**, 3539–3549.
- Chen X, Green AS, Macko AR, Yates DT, Kelly AC & Limesand SW (2014). Enhanced insulin secretion responsiveness and islet adrenergic desensitization after chronic norepinephrine suppression is discontinued in fetal sheep. *Am J Physiol Endocrinol Metab* **306**, E58–E64.
- Chen X, Kelly AC, Yates DT, Macko AR, Lynch RM & Limesand SW (2017). Islet adaptations in fetal sheep persist following chronic exposure to high norepinephrine. *J Endocrinol* **232**, 285–295.
- Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG & Crow MT (2000). The β_2 -adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G_i -dependent coupling to phosphatidylinositol 3'-kinase. *Circ Res* **87**, 1172–1179.
- Chiou WL, Jeong HY, Chung SM & Wu TC (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. *Pharm Res* **17**, 135–140.
- Claris O, Beltrand J & Levy-Marchal C (2010). Consequences of intrauterine growth and early neonatal catch-up growth. *Semin Perinatol* **34**, 207–210.
- Coleman ME, Ekeren PA & Smith SB (1988). Lipid synthesis and adipocyte growth in adipose tissue from sheep chronically fed a beta-adrenergic agent. *J Anim Sci* **66**, 372–378.
- Collins S, Caron MG & Lefkowitz RJ (1991). Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression. *Annu Rev Physiol* **53**, 497–508.
- Communal C, Singh K, Sawyer DB & Colucci WS (1999). Opposing effects of β_1 - and β_2 -adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. *Circulation* **100**, 2210–2212.
- Consolo NR, Rodriguez FD, Goulart RS, Frassetto MO, Ferrari VB & Silva LF (2015). Zilpaterol hydrochloride improves feed efficiency and changes body composition in nonimplanted Nellore heifers. *J Anim Sci* **93**, 4948–4955.
- Crispi F, Bijnens B, Figueras F, Bartrons J, Eixarch E, Le Noble F, Ahmed A & Gratacos E (2010). Fetal growth restriction results in remodeled and less efficient hearts in children. *Circulation* **121**, 2427–2436.
- Danielson L, McMillen IC, Dyer JL & Morrison JL (2005). Restriction of placental growth results in greater hypotensive response to α -adrenergic blockade in fetal sheep during late gestation. *J Physiol* **563**, 611–620.
- Davis MA, Macko AR, Steyn LV, Anderson MJ & Limesand SW (2015). Fetal adrenal demedullation lowers circulating norepinephrine and attenuates growth restriction but not reduction of endocrine cell mass in an ovine model of intrauterine growth restriction. *Nutrients* **7**, 500–516.
- De Blasio MJ, Gatford KL, McMillen IC, Robinson JS & Owens JA (2007). Placental restriction of fetal growth increases insulin action, growth, and adiposity in the young lamb. *Endocrinology* **148**, 1350–1358.
- De Blasio MJ, Gatford KL, Robinson JS & Owens JA (2006). Placental restriction alters circulating thyroid hormone in the young lamb postnatally. *Am J Physiol Regul Integr Comp Physiol* **291**, R1016–R1024.
- Despres G, Veissier I & Boissy A (2002). Effect of autonomic blockers on heart period variability in calves: evaluation of the sympathovagal balance. *Physiol Res* **51**, 347–353.
- Dulloo AG (2006). Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. *Horm Res* **65** (Suppl. 3), 90–97.

- Eriksson J (2019). Developmental pathways and programming of diabetes: epidemiological aspects. *J Endocrinol* **242**, T95–T104.
- Ford SP, Hess BW, Schwobe MM, Nijland MJ, Gilbert JS, Vonnahme KA, Means WJ, Han H & Nathanielsz PW (2007). Maternal undernutrition during early to mid-gestation in the ewe results in altered growth, adiposity, and glucose tolerance in male offspring. *J Anim Sci* **85**, 1285–1294.
- Gaillard R, Steegers EA, Tiemeier H, Hofman A & Jaddoe VW (2013). Placental vascular dysfunction, fetal and childhood growth, and cardiovascular development: the generation R study. *Circulation* **128**, 2202–2210.
- Gale CR, Martyn CN, Kellingray S, Eastell R & Cooper C (2001). Intrauterine programming of adult body composition. *J Clin Endocrinol Metab* **86**, 267–272.
- Gardner DS, Fletcher AJ, Bloomfield MR, Fowden AL & Giussani DA (2002). Effects of prevailing hypoxaemia, acidaemia or hypoglycaemia upon the cardiovascular, endocrine and metabolic responses to acute hypoxaemia in the ovine fetus. *J Physiol* **540**, 351–366.
- Gatford KL, De Blasio MJ, Thavaneswaran P, Robinson JS, McMillen IC & Owens JA (2004). Postnatal ontogeny of glucose homeostasis and insulin action in sheep. *Am J Physiol Endocrinol Metab* **286**, E1050–E1059.
- Gatford KL, Simmons RA, De Blasio MJ, Robinson JS & Owens JA (2010). Review: Placental programming of postnatal diabetes and impaired insulin action after IUGR. *Placenta* **31**, S60–S65.
- Gatford KL, Sulaiman SA, Mohammad SN, De Blasio MJ, Harland ML, Simmons RA & Owens JA (2013). Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb. *PLoS One* **8**, e56553.
- Gavi S, Yin D, Shumay E, Wang HY & Malbon CC (2007). Insulin-like growth factor-I provokes functional antagonism and internalization of beta1-adrenergic receptors. *Endocrinology* **148**, 2653–2662.
- Gerich JE (2002). Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? *Diabetes* **51** (Suppl. 1), S117–S121.
- Gluckman PD, Hanson MA, Cooper C & Thornburg KL (2008). Effect of in utero and early-life conditions on adult health and disease. *N Engl J Med* **359**, 61–73.
- Greenough A, Nicolaides KH & Lagercrantz H (1990). Human fetal sympathoadrenal responsiveness. *Early Hum Dev* **23**, 9–13.
- Greenwood PL, Hunt AS, Hermanson JW & Bell AW (1998). Effects of birth weight and postnatal nutrition on neonatal sheep: I. Body growth and composition, and some aspects of energetic efficiency. *J Anim Sci* **76**, 2354–2367.
- Gu C, Ma YC, Benjamin J, Littman D, Chao MV & Huang XY (2000). Apoptotic signaling through the beta-adrenergic receptor. A new Gs effector pathway. *J Biol Chem* **275**, 20726–20733.
- Hadcock JR, Port JD, Gelman MS & Malbon CC (1992). Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of beta 2-adrenergic receptors in response to insulin. *J Biol Chem* **267**, 26017–26022.
- Hediger ML, Overpeck MD, Kuczmarski RJ, McGlynn A, Maurer KR & Davis WW (1998). Muscularity and fatness of infants and young children born small- or large-for-gestational-age. *Pediatrics* **102**, E60.
- Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA & Gluckman PD (1997). Insulin resistance in short children with intrauterine growth retardation. *J Clin Endocrinol Metab* **82**, 402–406.
- Ibanez L, Suarez L, Lopez-Bermejo A, Diaz M, Valls C & de Zegher F (2008). Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight. *J Clin Endocrinol Metab* **93**, 925–928.
- Inskip HM, Godfrey KM, Martin HJ, Simmonds SJ, Cooper C & Sayer AA; Southampton Women's Survey Study Group (2007). Size at birth and its relation to muscle strength in young adult women. *J Intern Med* **262**, 368–374.
- Jackson BT, Piasecki GJ, Cohn HE & Cohen WR (2000). Control of fetal insulin secretion. *Am J Physiol Regul Integr Comp Physiol* **279**, R2179–R2188.
- Jaquet D, Gaboriau A, Czernichow P & Levy-Marchal C (2000). Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. *J Clin Endocrinol Metab* **85**, 1401–1406.
- Jensen J, Brennesvik EO, Lai YC & Shepherd PR (2007). GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. *Cell Signal* **19**, 204–210.
- Jensen J, Ruzzin J, Jebens E, Brennesvik EO & Knardahl S (2005). Improved insulin-stimulated glucose uptake and glycogen synthase activation in rat skeletal muscles after adrenaline infusion: role of glycogen content and PKB phosphorylation. *Acta Physiol Scand* **184**, 121–130.
- Jimenez-Chillaron JC, Isganaitis E, Charalambous M, Gesta S, Pentinat-Pelegrin T, Faucette RR, Otis JP, Chow A, Diaz R, Ferguson-Smith A & Patti ME (2009). Intergenerational transmission of glucose intolerance and obesity by in utero undernutrition in mice. *Diabetes* **58**, 460–468.
- Jones CT & Ritchie JW (1978). The cardiovascular effects of circulating catecholamines in fetal sheep. *J Physiol* **285**, 381–393.
- Jornayvaz FR, Selz R, Tappy L & Theintz GE (2004). Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidation. *Metabolism* **53**, 847–851.
- Kahn CR (1978). Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. *Metabolism* **27**, 1893–1902.
- Kanzler SA, Januario AC & Paschoalini MA (2011). Involvement of beta3-adrenergic receptors in the control of food intake in rats. *Braz J Med Biol Res* **44**, 1141–1147.
- Kelly AC, Bidwell CA, Chen X, Macko AR, Anderson MJ & Limesand SW (2018). Chronic adrenergic signaling causes abnormal RNA expression of proliferative genes in fetal sheep islets. *Endocrinology* **159**, 3565–3578.
- Kelly AC, Davenport HM, Taska DJ, Camacho LE, Davis MA, Bidwell CA, Allen RE & Limesand SW (2017). β -Oxidation compensates for impaired glucose metabolism in skeletal muscle from intrauterine growth restricted sheep fetuses. *Reprod Sci* **24**, Suppl. 1, 200A, F-098.

- Kensara OA, Wootton SA, Phillips DI, Patel M, Jackson AA & Elia M; Hertfordshire Study Group (2005). Fetal programming of body composition: relation between birth weight and body composition measured with dual-energy X-ray absorptiometry and anthropometric methods in older Englishmen. *Am J Clin Nutr* **82**, 980–987.
- Leos RA, Anderson MJ, Chen X, Pugmire J, Anderson KA & Limesand SW (2010). Chronic exposure to elevated norepinephrine suppresses insulin secretion in fetal sheep with placental insufficiency and intrauterine growth restriction. *Am J Physiol Endocrinol Metab* **298**, E770–E778.
- Li C, Johnson MS & Goran MI (2001). Effects of low birth weight on insulin resistance syndrome in Caucasian and African-American children. *Diabetes Care* **24**, 2035–2042.
- Limesand SW & Rozance PJ (2017). Fetal adaptations in insulin secretion result from high catecholamines during placental insufficiency. *J Physiol* **595**, 5103–5113.
- Limesand SW, Rozance PJ, Macko AR, Anderson MJ, Kelly AC & Hay WW Jr (2013). Reductions in insulin concentrations and beta-cell mass precede growth restriction in sheep fetuses with placental insufficiency. *Am J Physiol Endocrinol Metab* **304**, E516–E523.
- Limesand SW, Rozance PJ, Smith D & Hay WW Jr (2007). Increased insulin sensitivity and maintenance of glucose utilization rates in fetal sheep with placental insufficiency and intrauterine growth restriction. *Am J Physiol Endocrinol Metab* **293**, E1716–E1725.
- Limesand SW, Rozance PJ, Zerbe GO, Hutton JC & Hay WW Jr (2006). Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. *Endocrinology* **147**, 1488–1497.
- Liu H, Schultz CG, De Blasio MJ, Peura AM, Heinemann GK, Harryanto H, Hunter DS, Wooldridge AL, Kind KL, Giles LC, Simmons RA, Owens JA & Gatford KL (2015). Effect of placental restriction and neonatal exendin-4 treatment on postnatal growth, adult body composition, and in vivo glucose metabolism in the sheep. *Am J Physiol Endocrinol Metab* **309**, E589–E600.
- Louey S, Cock ML, Stevenson KM & Harding R (2000). Placental insufficiency and fetal growth restriction lead to postnatal hypotension and altered postnatal growth in sheep. *Pediatr Res* **48**, 808–814.
- Macko AR, Yates DT, Chen X, Green AS, Kelly AC, Brown LD & Limesand SW (2013). Elevated plasma norepinephrine inhibits insulin secretion, but adrenergic blockade reveals enhanced β -cell responsiveness in an ovine model of placental insufficiency at 0.7 of gestation. *J Dev Orig Health Dis* **4**, 402–410.
- Macko AR, Yates DT, Chen X, Shelton LA, Kelly AC, Davis MA, Camacho LE, Anderson MJ & Limesand SW (2016). Adrenal demedullation and oxygen supplementation independently increase glucose-stimulated insulin concentrations in fetal sheep with intrauterine growth restriction. *Endocrinology* **157**, 2104–2115.
- McMillen IC, Edwards LJ, Duffield J & Muhlhausler BS (2006). Regulation of leptin synthesis and secretion before birth: implications for the early programming of adult obesity. *Reproduction* **131**, 415–427.
- McMillen IC, MacLaughlin SM, Muhlhausler BS, Gentili S, Duffield JL & Morrison JL (2008). Developmental origins of adult health and disease: the role of periconceptional and foetal nutrition. *Basic Clin Pharmacol Toxicol* **102**, 82–89.
- McMillen IC & Robinson JS (2005). Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Rev* **85**, 571–633.
- MacRae JC, Skene PA, Connell A, Buchan V & Lobley GE (1988). The action of the beta-agonist clenbuterol on protein and energy metabolism in fattening wether lambs. *Br J Nutr* **59**, 457–465.
- Maltin CA, Delday MI, Hay SM, Innes GM & Williams PE (1990). Effects of bovine pituitary growth hormone alone or in combination with the beta-agonist clenbuterol on muscle growth and composition in veal calves. *Br J Nutr* **63**, 535–545.
- Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T, Giudice A, Guzzi U, Landi M & Le Fur G (1996). Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. *Br J Pharmacol* **117**, 435–442.
- Miniaci MC, Bucci M, Santamaria R, Irace C, Cantalupo A, Cirino G & Scotto P (2013). CL316,243, a selective beta3-adrenoceptor agonist, activates protein translation through mTOR/p70S6K signaling pathway in rat skeletal muscle cells. *Pflugers Arch* **465**, 509–516.
- Morisio C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, Sadoshima J & Trimarco B (2005). Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. *Circ Res* **96**, 180–188.
- Morrison JL (2008). Sheep models of intrauterine growth restriction: fetal adaptations and consequences. *Clin Exp Pharmacol Physiol* **35**, 730–743.
- Muhlhausler BS, Duffield JA, Ozanne SE, Pilgrim C, Turner N, Morrison JL & McMillen IC (2009). The transition from fetal growth restriction to accelerated postnatal growth: a potential role for insulin signalling in skeletal muscle. *J Physiol* **587**, 4199–4211.
- Owens JA, Gatford KL, De Blasio MJ, Edwards LJ, McMillen IC & Fowden AL (2007a). Restriction of placental growth in sheep impairs insulin secretion but not sensitivity before birth. *J Physiol* **584**, 935–949.
- Owens JA, Thavaneswaran P, De Blasio MJ, McMillen IC, Robinson JS & Gatford KL (2007b). Sex-specific effects of placental restriction on components of the metabolic syndrome in young adult sheep. *Am J Physiol Endocrinol Metab* **292**, E1879–E1889.
- Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S & Vaag AA (2005). Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. *Diabetologia* **48**, 547–552.
- Papas KK, Pisanía A, Wu H, Weir GC & Colton CK (2007). A stirred microchamber for oxygen consumption rate measurements with pancreatic islets. *Biotechnol Bioeng* **98**, 1071–1082.
- Pendleton AL, Humphreys LR, Davis MA, Camacho LE, Anderson MJ & Limesand SW (2019). Increased pyruvate dehydrogenase activity in skeletal muscle of growth restricted ovine fetuses. *Am J Physiol Regul Integr Comp Physiol* **317**, R513–R520.

- Petterson JA, Dunshea FR, Ehrhardt RA & Bell AW (1993). Pregnancy and undernutrition alter glucose metabolic responses to insulin in sheep. *J Nutr* **123**, 1286–1295.
- Riyami NA, Walker MG, Proctor LK, Yinon Y, Windrim RC & Kingdom JCP (2011). Utility of head/abdomen circumference ratio in the evaluation of severe early-onset intrauterine growth restriction. *J Obstet Gynaecol Can* **33**, 715–719.
- Rozance PJ & Hay WW Jr (2016). New approaches to management of neonatal hypoglycemia. *Matern Health Neonatol Perinatol* **2**, 3.
- Rozance PJ, Zastoupil L, Wesolowski SR, Goldstrohm DA, Strahan B, Cree-Green M, Sheffield-Moore M, Meschia G, Hay WW Jr, Wilkening RB & Brown LD (2018). Skeletal muscle protein accretion rates and hindlimb growth are reduced in late gestation intrauterine growth-restricted fetal sheep. *J Physiol* **596**, 67–82.
- Sayer AA, Syddall HE, Dennison EM, Gilbody HJ, Duggleby SL, Cooper C, Barker DJ & Phillips DI (2004). Birth weight, weight at 1 y of age, and body composition in older men: findings from the Hertfordshire Cohort Study. *Am J Clin Nutr* **80**, 199–203.
- Scheidegger K, O'Connell M, Robbins DC & Danforth E Jr (1984). Effects of chronic beta-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. *J Clin Endocrinol Metab* **58**, 895–903.
- Seino S, Shibasaki T & Minami K (2011). Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *J Clin Invest* **121**, 2118–2125.
- Simmons RA, Templeton LJ & Gertz SJ (2001). Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. *Diabetes* **50**, 2279–2286.
- Simonetta G, Rourke AK, Owens JA, Robinson JS & McMillen IC (1997). Impact of placental restriction on the development of the sympathoadrenal system. *Pediatr Res* **42**, 805–811.
- Smith KE, Kelly AC, Min CG, Weber CS, McCarthy FM, Steyn LV, Badarinarayana V, Stanton JB, Kitzmann JP, Strop P, Gruessner AC, Lynch RM, Limesand SW & Papas KK (2017). Acute ischemia induced by high density culture increases cytokine expression and diminishes the function and viability of highly purified human islets of Langerhans. *Transplantation* **201**, 2705–2712.
- Soto N, Bazaes RA, Pena V, Salazar T, Avila A, Iniguez G, Ong KK, Dunger DB & Mericq MV (2003). Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. *J Clin Endocrinol Metab* **88**, 3645–3650.
- Soto SM, Blake AC, Wesolowski SR, Rozance PJ, Barthel KB, Gao B, Hetrick B, McCurdy CE, Garza NG, Hay WW Jr, Leinwand LA, Friedman JE & Brown LD (2017). Myoblast replication is reduced in the IUGR fetus despite maintained proliferative capacity in vitro. *J Endocrinol* **232**, 475–491.
- Spence D, Stewart MC, Alderdice FA, Patterson CC & Halliday HL (2012). Intra-uterine growth restriction and increased risk of hypertension in adult life: a follow-up study of 50-year-olds. *Public Health* **126**, 561–565.
- Spiroski AM, Oliver MH, Jaquiere AL, Prickett TCR, Espiner EA, Harding JE & Bloomfield FH (2018). Postnatal effects of intrauterine treatment of the growth-restricted ovine fetus with intra-amniotic insulin-like growth factor-1. *J Physiol* **596**, 5925–5945.
- Stanley CA, Rozance PJ, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Simmons RA, Sperling MA, Weinstein DA, White NH & Wolfsdorf JI (2015). Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management. *J Pediatr* **166**, 1520–1525.
- Stephens CT, Uwaydah N, Kramer GC, Prough DS, Salter M & Kinsky MP (2011). Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep. *Shock* **36**, 303–311.
- Thorn SR, Brown LD, Rozance PJ, Hay WW Jr & Friedman JE (2013). Increased hepatic glucose production in fetal sheep with intrauterine growth restriction is not suppressed by insulin. *Diabetes* **62**, 65–73.
- Thorn SR, Regnault TR, Brown LD, Rozance PJ, Keng J, Roper M, Wilkening RB, Hay WW Jr & Friedman JE (2009). Intrauterine growth restriction increases fetal hepatic gluconeogenic capacity and reduces messenger ribonucleic acid translation initiation and nutrient sensing in fetal liver and skeletal muscle. *Endocrinology* **150**, 3021–3030.
- Torneke K, Ingavast Larsson C & Appelgren LE (1998). A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle. *J Vet Pharmacol Ther* **21**, 388–392.
- Wallace JM (2019). Competition for nutrients in pregnant adolescents: consequences for maternal, conceptus and offspring endocrine systems. *J Endocrinol* **242**, T1–T19.
- Wallace JM, Milne JS, Aitken RP, Horgan GW & Adam CL (2018). Ovine prenatal growth restriction impacts glucose metabolism and body composition throughout life in both sexes. *Reproduction* **156**, 103–119.
- Wang H, Doronin S & Malbon CC (2000). Insulin activation of mitogen-activated protein kinases Erk1,2 is amplified via beta-adrenergic receptor expression and requires the integrity of the Tyr350 of the receptor. *J Biol Chem* **275**, 36086–36093.
- Wettschurek N & Offermanns S (2005). Mammalian G proteins and their cell type specific functions. *Physiol Rev* **85**, 1159–1204.
- Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S, Barrett-Connor E, Bhargava SK, Birgisdottir BE, Carlsson S, de Rooij SR, Dyck RF, Eriksson JG, Falkner B, Fall C, Forsen T, Grill V, Gudnason V, Hulman S, Hypponen E, Jeffreys M, Lawlor DA, Leon DA, Minami J, Mishra G, Osmond C, Power C, Rich-Edwards JW, Roseboom TJ, Sachdev HS, Syddall H, Thorsdottir I, Vanhala M, Wadsworth M & Yarbrough DE (2008). Birth weight and risk of type 2 diabetes: a systematic review. *JAMA* **300**, 2886–2897.
- Williams PE, Pagliani L, Innes GM, Pennie K, Harris CI & Garthwaite P (1987). Effects of a beta-agonist (clenbuterol) on growth, carcass composition, protein and energy metabolism of veal calves. *Br J Nutr* **57**, 417–428.

- Yates DT, Cadaret CN, Beede KA, Riley HE, Macko AR, Anderson MJ, Camacho LE & Limesand SW (2016). Intrauterine growth-restricted sheep fetuses exhibit smaller hindlimb muscle fibers and lower proportions of insulin-sensitive Type I fibers near term. *Am J Physiol Regul Integr Comp Physiol* **310**, R1020–R1029.
- Yates DT, Chen X & Limesand SW (2012a). Environmental heat stress impairs placental function, fetal growth and development, and postnatal performance in livestock. In *Environmental Physiology of Livestock*, 1st edn, ed. Collier RJ & Collier JL, pp. 209–228. John Wiley & Sons, Inc., Hoboken, NJ, USA.
- Yates DT, Clarke DS, Macko AR, Anderson MJ, Shelton LA, Nearing M, Allen RE, Rhoads RP & Limesand SW (2014). Myoblasts from intrauterine growth-restricted sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller semitendinosus myofibres. *J Physiol* **592**, 3113–3125.
- Yates DT, Macko AR, Chen X, Green AS, Kelly AC, Anderson MJ, Fowden AL & Limesand SW (2012b). Hypoxemia-induced catecholamine secretion from adrenal chromaffin cells inhibits glucose-stimulated hyperinsulinemia in fetal sheep. *J Physiol* **590**, 5439–5447.
- Yates DT, Petersen JL, Schmidt TB, Cadaret CN, Barnes TL, Posont RJ & Beede KA (2018). ASAS-SSR triennial reproduction symposium: looking back and moving forward – how reproductive physiology has evolved: fetal origins of impaired muscle growth and metabolic dysfunction: lessons from the heat-stressed pregnant ewe. *J Anim Sci* **96**, 2987–3002.
- Yliharsila H, Kajantie E, Osmond C, Forsen T, Barker DJ & Eriksson JG (2007). Birth size, adult body composition and muscle strength in later life. *Int J Obes (Lond)* **31**, 1392–1399.
- Zanardo V, Fanelli T, Weiner G, Fanos V, Zaninotto M, Visentin S, Cavallin F, Trevisanuto D & Cosmi E (2011). Intrauterine growth restriction is associated with persistent aortic wall thickening and glomerular proteinuria during infancy. *Kidney Int* **80**, 119–123.
- Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ & Siddiqui MA (2000). Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. *Circulation* **102**, 344–350.
- Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK & Xiao RP (2001). Dual modulation of cell survival and cell death by β_2 -adrenergic signaling in adult mouse cardiac myocytes. *Proc Natl Acad Sci U S A* **98**, 1607–1612.

Additional information

Competing interests

No conflicts of interest, financial or otherwise, are declared by the authors.

Author contributions

All work was conducted at the University of Arizona's Agricultural Research Centre. D.T.Y., L.E.C. and S.W.L. conceived and designed the study; D.T.Y., L.E.C., A.C.K., L.V.S., M.A.D., A.T.A., M.J.A., R.G., R.E.A., K.K.P., W.W.H. and S.W.L. were involved in the acquisition, analysis and interpretation of data; D.T.Y., L.E.C. and S.W.L. prepared figures; D.T.Y., L.E.C. and S.W.L. drafted the manuscript. All authors edited and revised the manuscript. All authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

Funding

The Bill and Melinda Gates Foundation Global Health Grant Number OPP1066912 funded this project (Principal Investigator, S. W. Limesand). This work was also supported by the National Institutes of Health (NIH) R01DK-084842 (Principal Investigator, S. W. Limesand). D. T. Yates was supported by National Institute of Food and Agriculture Postdoctoral Fellowship Award No. 2012-67012-19855 (Principal Investigator, D. T. Yates) and T32 HL007249 (Principal Investigator, C. C. Gregorio). L. E. Camacho was supported by National Institute of Food and Agriculture Postdoctoral Fellowship Award No. 2015-03545 (Principal Investigator, L. E. Camacho) and T32 HL007249 (Principal Investigator, C. C. Gregorio). A. T. Antolic was supported by T32 HL007249 (Principal Investigator, C. C. Gregorio). W. W. Hay was supported by NIH T32 HD007186 (Principal Investigator and Project Director), NIH K12 HD068372 (PD) and NIH UL1TR001082 (Component Director).

Acknowledgements

We would like to thank Nathan R. Steffens, Hailey M. Davenport, Craig Weber and Mandie M. Dunham for their technical assistance.

Keywords

cardiovascular dysfunction, developmental origins of health and disease, fetal programming, glucose disposal rates, metabolic syndrome